<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma - Weis, S - 2013 | Cochrane Library</title> <meta content="Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma - Weis, S - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003046.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma - Weis, S - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003046.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003046.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma" name="citation_title"/> <meta content="Sebastian Weis" name="citation_author"/> <meta content="University of Leipzig" name="citation_author_institution"/> <meta content="sebastian.weis@medizin.uni-leipzig.de" name="citation_author_email"/> <meta content="Annegret Franke" name="citation_author"/> <meta content="Universität Leipzig" name="citation_author_institution"/> <meta content="Joachim Mössner" name="citation_author"/> <meta content="University of Leipzig" name="citation_author_institution"/> <meta content="Janus C Jakobsen" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet" name="citation_author_institution"/> <meta content="Konrad Schoppmeyer" name="citation_author"/> <meta content="Euregio‐Klinik GmbH" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD003046.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/12/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003046.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003046.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003046.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetic Acid [administration &amp; dosage]; Administration, Cutaneous; Carcinoma, Hepatocellular [mortality, *therapy]; Catheter Ablation [*methods, mortality]; Ethanol [administration &amp; dosage]; Hepatectomy [mortality]; Liver Neoplasms [mortality, *therapy]; Microwaves [therapeutic use]; Randomized Controlled Trials as Topic; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003046.pub3&amp;doi=10.1002/14651858.CD003046.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="4nUWI3Cc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003046\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003046\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fr","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003046.pub3",title:"Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma",firstPublishedDate:"Dec 19, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato‐Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003046.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003046.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003046.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003046.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003046.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003046.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003046.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003046.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003046.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003046.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2096 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003046.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-sec1-0006"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/appendices#CD003046-sec1-0012"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/table_n/CD003046StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/table_n/CD003046StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/information#CD003046-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sebastian Weis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/information#CD003046-cr-0003">Annegret Franke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/information#CD003046-cr-0004">Joachim Mössner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/information#CD003046-cr-0005">Janus C Jakobsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003046.pub3/information#CD003046-cr-0006">Konrad Schoppmeyer</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/information/en#CD003046-sec1-0015">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 December 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003046.pub3">https://doi.org/10.1002/14651858.CD003046.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003046-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003046-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003046-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003046-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003046-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003046-abs-0001" lang="en"> <section id="CD003046-abs1-0001"> <h3 class="title" id="CD003046-abs1-0001">Background</h3> <p>Hepatocellular carcinoma is the fifth most common cancer worldwide. Percutaneous interventional therapies, such as radiofrequency (thermal) ablation (RFA), have been developed for early hepatocellular carcinoma. RFA competes with other interventional techniques such as percutaneous ethanol injection, surgical resection, and liver transplantation. The potential benefits and harms of RFA compared with placebo, no intervention, chemotherapy, hepatic resection, liver transplantation, or other interventions are unclear. </p> </section> <section id="CD003046-abs1-0002"> <h3 class="title" id="CD003046-abs1-0002">Objectives</h3> <p>To assess the beneficial and harmful effects of RFA versus placebo, no intervention, or any other therapeutic approach in patients with hepatocellular carcinoma. </p> </section> <section id="CD003046-abs1-0003"> <h3 class="title" id="CD003046-abs1-0003">Search methods</h3> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL)<i>,</i> MEDLINE, EMBASE, and ISI Web of Science to September 2012. We handsearched meeting abstracts from ASCO, ESMO, AASLD, EASL, APASL, and references of articles. We also contacted researchers in the field (last search September 2012). </p> </section> <section id="CD003046-abs1-0004"> <h3 class="title" id="CD003046-abs1-0004">Selection criteria</h3> <p>We considered for inclusion randomised clinical trials investigating the effects of RFA versus placebo, no intervention, or any other therapeutic approach on hepatocellular carcinoma patients regardless of blinding, language, and publication status. </p> </section> <section id="CD003046-abs1-0005"> <h3 class="title" id="CD003046-abs1-0005">Data collection and analysis</h3> <p>Two review authors independently performed the selection of trials, assessment of risk of bias, and data extraction. We contacted principal investigators for missing information. We analysed hazard ratios (HR) as relevant effect measures for overall survival, two‐year survival, event‐free survival, and local recurrences with 95% confidence intervals (CI). In addition, we analysed dichotomous survival outcomes using risk ratios (RR). We used trial sequential analysis to control the risk of random errors ('play of chance'). </p> </section> <section id="CD003046-abs1-0006"> <h3 class="title" id="CD003046-abs1-0006">Main results</h3> <p>We identified no trials comparing RFA versus placebo, no intervention, or liver transplantation. We identified and included 11 randomised clinical trials with 1819 participants that included four comparisons: RFA versus hepatic resection (three trials, 578 participants); RFA versus percutaneous ethanol injection (six trials, 1088 participants) including one three‐armed trial that also investigated RFA versus acetic acid injection; RFA versus microwave ablation (one trial, 72 participants); and RFA versus laser ablation (one trial, 81 participants). Ten of the eleven included trials reported on the primary outcome of this review, overall survival. Rates of major complications or procedure‐related deaths were reported in 10 trials. The overall risk of bias was considered low in five trials and high in six trials. For a subgroup analysis, we included only low risk of bias trials. Regarding the comparison RFA versus hepatic resection, there was moderate‐quality evidence from two low risk of bias trials that hepatic resection seems more effective than RFA regarding overall survival (HR 0.56; 95% CI 0.40 to 0.78) and two‐year survival (HR 0.38; 95% CI 0.17 to 0.84). However, if we included a third trial with high risk of bias, the difference became insignificant (overall survival: HR 0.71; 95% CI 0.44 to 1.15). With regards to the outcomes event‐free survival and local progression, hepatic resection also yielded better results than RFA. However, the number of complications was higher in surgically treated participants (odds ratio (OR) 8.24; 95% CI 2.12 to 31.95). RFA seemed superior to percutaneous ethanol or acetic acid injection regarding overall survival (HR 1.64; 95% CI 1.31 to 2.07). The RR for mortality was also in favour of RFA, but did not reach statistical significance (150/490 (30.6%) people in the percutaneous ethanol or acetic acid group versus 119/496 (24.0%) people in the RFA group; RR 1.76; 95% CI 0.97 to 3.22). The proportion of adverse events did not differ significantly between RFA and percutaneous ethanol or acetic acid injection (HR 0.70; 95% CI 0.33 to 1.48). Trial sequential analyses revealed that the number of participants in the included trials was insufficient and that more trials are needed to assess the effects of RFA versus other interventions. </p> </section> <section id="CD003046-abs1-0007"> <h3 class="title" id="CD003046-abs1-0007">Authors' conclusions</h3> <p>The effects of RFA versus no intervention, chemotherapeutic treatment, or liver transplantation are unknown. We found moderate‐quality evidence that hepatic resection is superior to RFA regarding survival. However, RFA might be associated with fewer complications and a shorter hospital stay than hepatic resection. We found moderate‐quality evidence showing that RFA seems superior to percutaneous ethanol injection regarding survival. There were too sparse data to recommend or refute ablation achieved by techniques other than RFA. More randomised clinical trials with low risk of bias and low risks of random errors assessing the effect of RFA are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003046-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003046-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003046-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003046-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003046-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003046-abs-0009">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003046-abs-0005" lang="en"> <h3>Radiofrequency ablation for the treatment of liver cancer (hepatocellular carcinoma)</h3> <p><b>Background</b> </p> <p>Liver cancer (hepatocellular carcinoma) is the fifth most common cancer worldwide. In the majority of patients, hepatocellular carcinoma is diagnosed at advanced stages of the disease and is mostly accompanied by liver cirrhosis. To date, there is no medical cure for patients with hepatocellular carcinoma, and treatment aims to slow tumour growth. In high‐income countries, about 30% of patients present with the more favourable early hepatocellular carcinoma. For these patients, percutaneous ablation techniques (destruction of the cancer cells by heat, cold, or chemical substances such as ethanol), surgical resection (removal of part of the liver), and liver transplantation (which is limited by organ donor shortage) are currently considered potentially curative treatments. Radiofrequency (thermal) ablation (RFA) is the most elaborated of the percutaneous interventions, so far. Heat caused by alternating electric current is administered by probes that are inserted through the skin (percutaneously). </p> <p><b>Study characteristics</b> </p> <p>The review authors searched the medical literature in order to clarify the role of RFA for the treatment of hepatocellular carcinoma and to compare its benefits and harms with no treatment, placebo (a pretend treatment), or other treatments (such as hepatic resection, percutaneous ethanol injection (PEI), percutaneous acetic acid injection (PAI), laser or microwave ablation, and liver transplantation). We looked for randomised clinical trials (where people were allocated at random to one of two or more treatments groups) of people with hepatocellular carcinoma who were able to receive RFA. Evidence is current to September 2013. </p> <p><b>Key results and quality of evidence</b> </p> <p>We found no trials comparing RFA versus no intervention, placebo, chemotherapy, or liver transplantation. </p> <p>The review authors found moderate‐quality evidence from two trials with low risk of bias (where there was a low risk of a flaw in study design, method of collecting or interpreting results) randomising 578 patients suggesting that hepatic resection yielded better results regarding overall survival (the length of time that the patient remains alive), event‐free survival (time that the person remains free of cancer or a certain symptom relating to cancer), and progression (time that the patient lives with cancer without it getting worse) compared with RFA. However, as resection is a more invasive procedure, resection has an eight times higher risk of major complications compared with RFA. Resected patients stayed twice as long in the hospital as the RFA patients. Moderate‐quality evidence suggested that RFA prolongs survival and decreases recurrences (where the cancer returns) compared with PEI or PAI. This conclusion was based on data from six randomised clinical trials with 1088 participants. Some patients developed side effects such as fever, rash, and pain. These occurred at the same frequency in both treatment groups. We calculated the number of patients that would be required to judge a relative risk reduction (relative risk is a comparison of the risk of an event happening for one treatment group compared with another treatment group) for survival of 20%. The review authors found that for both comparisons, that is RFA versus PEI or PAI, and RFA versus resection, the number of patients in the included trials was too low to reach valid conclusions. No firm conclusion can be drawn from the comparison of RFA against other interventional techniques or combination approaches. The information provided by the single trials was limited. More randomised clinical trials with low risks of bias (that is low risks of systematic errors, leading to overestimation of benefits and underestimation of harms) and low risk of play of chance (that is random errors, leading to overestimation or underestimation of benefits and harms) are required. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003046-sec1-0007" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003046-sec1-0007"></div> <h3 class="title" id="CD003046-sec1-0008">Implications for practice</h3> <section id="CD003046-sec1-0008"> <p>In this update of the previous Cochrane review from 2004 (<a href="./references#CD003046-bbs2-0112" title="GalandiD , AntesG . Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews2004, Issue 2. [DOI: 10.1002/14651858.CD003046] ">Galandi 2004</a>), we identified 11 trials comparing radiofrequency ablation (RFA) versus other interventions that fulfilled the inclusion criteria. There is moderate‐quality evidence from two trials with low risk of bias that hepatic resection seems to yield better results than RFA in patients with early hepatocellular carcinoma. This is counterbalanced by an increased rate of adverse events and by a longer hospital stay in surgically treated patients requiring a cautious choice of the appropriate therapy for any individual patient. There is moderate‐quality evidence that RFA seems to be to be more effective than percutaneous ethanol injection (PEI) or percutaneous acetic acid injection (PAI) in early hepatocellular carcinoma. However, trial sequential analyses showed that only 40% of the required number of patients were recruited in order to judge a relative risk reduction of 20%, therefore, more trials with low risk of bias are needed to confirm our results. A small number of studies have been conducted to compare RFA versus other interventions such as microwave and laser ablation. Due to a high risk of bias in these trials, these interventions cannot yet be recommended for clinical practice. </p> </section> <h3 class="title" id="CD003046-sec1-0009">Implications for research</h3> <section id="CD003046-sec1-0009"> <p>The is a need for well‐designed, sufficiently powered, multicentre trials with low risk of bias comparing RFA versus hepatic resection, PEI, or PAI in patients with hepatocellular carcinoma. Although there is evidence from two low risk of bias trials that hepatic resection yields better survival rates, more data are needed in order to confirm these results. There is a lack of evidence whether RFA can be used as a bridging therapy for patients that are listed for liver transplantation. </p> <p>In general, trial outcomes should comprise overall survival, event‐free survival, adverse events, and quality of life. With regards to increasing financial restrictions in public healthcare systems, the economic costs should also be investigated. In addition, a sufficiently extended follow‐up period should be ensured in every trial. To obtain a higher level of external validity, trials involving RFA should be conducted as multicentre trials because surgical as well as percutaneous interventions are strongly affected by the individual experience of the physician(s)/investigator(s). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003046-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003046-sec1-0001"></div> <div class="table" id="CD003046-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hepatic resection compared with radiofrequency ablation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hepatic resection compared with radiofrequency ablation for early hepatocellular carcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population: 578 patients with early HCC</b> </p> <p><b>Intervention: hepatic resection</b> </p> <p><b>Comparison: RFA</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Hazard ratio (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.44 to 1.15)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++O<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2‐year survival‐</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.51 (0.24 to 1.08)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++O<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Event‐free survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.54 to 0.91)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++O<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Local progression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.48 (0.28 to 0.82)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 trial reported on local progression.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate of complications</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.24 (2.12 to 31.95)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistical method is: odds ratio (M‐H, random, 95% CI)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay (days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.18 (1.97 to 2.39)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistical method is: standard. mean difference (IV, random, 95% CI)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; HCC: hepatocellular carcinoma; HR: hazard ratio; PAI: percutaneous acetic acid injection; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003046-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Percutaneous ethanol injection compared with radiofrequency ablation for early hepatocellular carcinoma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Percutaneous ethanol injection compared with radiofrequency ablation for early hepatocellular carcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population: 1088 patients with early HCC</b> </p> <p><b>Intervention: PEI/PAI</b> </p> <p><b>Comparison: RFA</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Hazard ratio (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.64 (1.31 to 2.07)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1088</p> <p>(6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As there were 2 three‐armed trials, we report 6 trials with 8 comparisons.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2‐year survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.82 (1.34 to 2.47)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>715</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Event‐free survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.55 (1.31 to 1.85)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>949</p> <p>(5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Local progression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.44 (1.71 to 3.49)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>678</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate of complications</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.33 to 1.48)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1088</p> <p>(6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistical method is: odds ratio (M‐H, random, 95% CI).</p> <p>As there were 2 three‐armed trials, it is 5 studies with 7 comparisons.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐1.50 (‐3.69 to 0.68)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>576</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistical method is: standard. Mean difference (IV, random, 95% CI).</p> <p>As there were 2 three‐armed trials, it is 3 studies with 5 comparisons.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; HCC: hepatocellular carcinoma; HR: hazard ratio; PAI: percutaneous acetic acid injection; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003046-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clinical characteristics of patients treated with radiofrequency ablation or percutaneous ethanol injection</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""></td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b> Child‐Pugh </b> </p> </td> <td align="center" class="table-header" colspan="5" rowspan="1" valign=""> <p><b> Aetiology</b> </p> </td> <td align="center" class="table-header" colspan="4" rowspan="1" valign=""> <p><b>Tumour</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b> Overall survival</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Italian Trials </b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>A</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>B</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>HBV</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>HCV</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>HBC+HCV</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Alcohol</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Others</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Mean number of nodules</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>1 tumour</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Mean size</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Size &lt; 2 cm</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>HR (95% CI)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.65 to 2.01)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.71 to 2.14)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0007" title="LencioniR , AllgaierHP , CioniD , OlschewskiM , DeibertP , CrocettiL , et al. Small hepatocellular carcinoma: randomized comparison of radio‐frequency thermal ablation and percutaneous ethanol injection. Radiology2003;228:235‐40. ">Lencioni 2003</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.55 to 45.82)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Mean</i> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.84 to 1.83)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>East‐Asian Trials </b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.77</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.08 (1.02 to 4.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.01 (1.03 to 3.92)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.73</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.86 (0.33 to 0.88)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Mean</i> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.95 (1.38 to 2.75)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Student's t‐test</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p>CI: confidence interval; HBV: hepatitis B virus; HCV: hepatitis C virus; HR: hazard ratio; n.s.: not significant (P value &gt; 0.05); PEI: percutaneous ethanol injection; RFA: radiofrequency ablation. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003046-sec1-0002" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003046-sec1-0002"></div> <section id="CD003046-sec2-0001"> <h3 class="title" id="CD003046-sec2-0001">Description of the condition</h3> <section id="CD003046-sec3-0001"> <h4 class="title">Epidemiology and risk factors</h4> <p>Hepatocellular carcinoma (liver cancer) is the fifth most common cancer worldwide (<a href="./references#CD003046-bbs2-0063" title="El‐SeragHB , RudolphKL . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology2007;132(7):2557‐76. ">El Serag 2007</a>). The highest incidence of hepatocellular carcinoma is found in regions with endemic hepatitis B virus (HBV) such as Eastern Asia and Central Africa. A rising incidence of hepatocellular carcinoma in high‐income countries has been reported, along with a decrease in high‐incidence areas (<a href="./references#CD003046-bbs2-0061" title="ElSeragHB , MasonAC . Rising incidence of hepatocellular carcinoma in the United States. New England Journal of Medicine1999;340:745‐50. ">El Serag 1999</a>; <a href="./references#CD003046-bbs2-0063" title="El‐SeragHB , RudolphKL . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology2007;132(7):2557‐76. ">El Serag 2007</a>; <a href="./references#CD003046-bbs2-0071" title="JepsenP , VilstrupH , TaroneRE , FriisS , SørensenHT . Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. International Journal of Cancer2007;121(7):1624‐6. ">Jepsen 2007</a>). This might be caused by differences in hepatitis C virus (HCV) prevalence (e.g. increase in the USA) (<a href="./references#CD003046-bbs2-0071" title="JepsenP , VilstrupH , TaroneRE , FriisS , SørensenHT . Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. International Journal of Cancer2007;121(7):1624‐6. ">Jepsen 2007</a>), and increased HBV vaccination rates (e.g. decrease in China) (<a href="./references#CD003046-bbs2-0063" title="El‐SeragHB , RudolphKL . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology2007;132(7):2557‐76. ">El Serag 2007</a>). Overall, 75% to 80% of patients with primary liver cancer are attributable to persistent viral infections with either HBV (50% to 55%) or HCV (25% to 30%). High consumption of alcohol; cumulative amount of aflatoxins in the liver over time; and metabolic disorders such as non‐alcoholic fatty liver disease, haemochromatosis, and alpha‐1‐antitrypsin deficiency are further risk factors for the development of cirrhosis and subsequent hepatocellular carcinoma (<a href="./references#CD003046-bbs2-0099" title="SørensenHT , MellemkjærL , JepsenP , ThulstrupAM , BaronJ , OlsenJH , et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. Journal of Clinical Gastroenterology2003;36:356‐9. ">Sørensen 2003</a>; <a href="./references#CD003046-bbs2-0048" title="BoschFX , RibesJ , DíazM , ClériesR . Primary liver cancer: worldwide incidence and trends. Gastroenterology2004;127:S5‐S16. ">Bosch 2004</a>; <a href="./references#CD003046-bbs2-0060" title="European Association for the Study of the Liver, European Organisation for Research and Treatment Of Cancer. EASL‐EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908‐43. ">EASL‐EORTC 2012</a>). Associations of primary liver cancer with diabetes (<a href="./references#CD003046-bbs2-0062" title="ElSeragHB , TranT , EverhartJE . Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology2004;126:460‐8. ">El Serag 2004</a>), obesity (<a href="./references#CD003046-bbs2-0054" title="CalleEE , RodriguezC , Walker‐ThurmondK , ThunMJ . Overweight, obesity, and mortality of cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine2003;348:1625‐38. ">Calle 2003</a>), and syndromes related to insulin resistance are subject of ongoing research, but their impact is currently unclear. </p> </section> <section id="CD003046-sec3-0002"> <h4 class="title">Prognosis</h4> <p>Liver cancer carries high mortality. In Europe and USA, the five‐year survival is below 10% (<a href="./references#CD003046-bbs2-0097" title="SchoppmeyerK , WeisS , MössnerJ , FleigWE . Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD006745.pub2] ">Schoppmeyer 2009</a>). In most patients, hepatocellular carcinoma is diagnosed at late stages of the disease and is mostly accompanied by liver cirrhosis. In high‐income countries, only about 30% of patients present with the more favourable early hepatocellular carcinoma (<a href="./references#CD003046-bbs2-0052" title="BruixJ , ShermanM , LlovetJM , BeaugrandM , LencioniR , BurroughsAK , et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona‐2000 EASL Conference. Journal of Hepatology2001;35:421‐30. ">Bruix 2001</a>). Percutaneous ablation techniques, surgical resection, and liver transplantation are currently considered potentially curative treatments for early hepatocellular carcinoma. </p> </section> <section id="CD003046-sec3-0003"> <h4 class="title">Diagnosis</h4> <p>Due to the neovascularity of hepatocellular carcinoma and its characteristic arterial hypervascularity and venous/late phase washout (so‐called hepatocellular carcinoma radiological hallmark) in rapid‐sequence cross‐sectional imaging, an accurate diagnosis of hepatocellular carcinoma lesions larger than 2 cm in diameter can be made non‐invasively in patients with cirrhosis. According to the current guidelines of the European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) (<a href="./references#CD003046-bbs2-0060" title="European Association for the Study of the Liver, European Organisation for Research and Treatment Of Cancer. EASL‐EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908‐43. ">EASL‐EORTC 2012</a>), non‐invasive diagnostic criteria for patients with cirrhosis and hepatocellular carcinoma are: </p> <p> <ul id="CD003046-lst1-0001"> <li> <p>for lesions larger than 2 cm: one positive imaging technique (four‐phase computed tomography or dynamic contrast enhanced magnetic resonance imaging (MRI)) </p> </li> <li> <p>for lesions from 1 to 2 cm: two coincidental techniques (computed tomography, MRI, or contrast‐enhanced ultrasound. </p> </li> </ul> </p> <p>Image‐guided biopsies of the tumour are common practice in cases of inconclusive radiological findings, that is, a lesion between 1 and 2 cm in diameter identified by only one imaging modality and such biopsies are mandatory for tumours in non‐cirrhotic livers (<a href="./references#CD003046-bbs2-0100" title="TakamoriR , WongLL , DangC , WongL . Needle‐tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary?. Liver Transplantation2000;6:67‐72. ">Takamori 2000</a>; <a href="./references#CD003046-bbs2-0060" title="European Association for the Study of the Liver, European Organisation for Research and Treatment Of Cancer. EASL‐EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908‐43. ">EASL‐EORTC 2012</a>). Elevated serum levels of alpha‐fetoprotein (AFP) that were proposed in addition to one typical radiological finding at the beginning of the century (<a href="./references#CD003046-bbs2-0052" title="BruixJ , ShermanM , LlovetJM , BeaugrandM , LencioniR , BurroughsAK , et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona‐2000 EASL Conference. Journal of Hepatology2001;35:421‐30. ">Bruix 2001</a>) have been discarded from the diagnostic scheme by the American Association for the Study of Liver Disease (AASLD) (<a href="./references#CD003046-bbs2-0053" title="BruixJ , ShermanM . Management of hepatocellular carcinoma. Hepatology2005;42:1208‐36. ">Bruix 2005</a>). Conversely, it is still regarded to be useful by EASL and EORTC (<a href="./references#CD003046-bbs2-0060" title="European Association for the Study of the Liver, European Organisation for Research and Treatment Of Cancer. EASL‐EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908‐43. ">EASL‐EORTC 2012</a>). </p> </section> </section> <section id="CD003046-sec2-0002"> <h3 class="title" id="CD003046-sec2-0002">Description of the intervention</h3> <p>Ablation techniques rely on the possibility to induce cell death by thermal or chemical means. The aim of the ablation is to completely destroy all tumour cells and thus provide cure of the cancer. The underlying liver disease (e.g. cirrhosis or hepatitis) is not affected by the treatment. </p> <p><i>Radiofrequency ablation or radiofrequency thermal ablation (RFA)</i> uses frictional heat to induce cell death from coagulation necrosis. After local anaesthesia of the skin, an RFA‐electrode is placed into the liver lesion under the guidance of magnetic resonance tomography, computed tomography, or ultrasound (<a href="./references#CD003046-bbs2-0066" title="GoldbergSN , GazelleGS , MuellerPR . Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. American Journal of Roentgenology2000;174(2):323‐31. ">Goldberg 2000</a>). A radiofrequency‐current‐generator is connected to the needle and a zero‐electrode is fixed onto the patient's back. Under short‐term analgesia‐sedation, energy is applied for a few minutes leading to spheric lesions of about 3 to 5 cm in diameter. When temperatures pace 60 °C, a coagulation necrosis is induced (<a href="./references#CD003046-bbs2-0084" title="MinamiY , KudoM . Radiofrequency ablation of hepatocellular carcinoma: current status. World Journal of Gastroenterology2010;2(11):417‐24. ">Minami 2010</a>; <a href="./references#CD003046-bbs2-0060" title="European Association for the Study of the Liver, European Organisation for Research and Treatment Of Cancer. EASL‐EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908‐43. ">EASL‐EORTC 2012</a>). Several investigations have shown the efficacy and the safety of the procedure (<a href="./references#CD003046-bbs2-0092" title="RossiS , DiStasiM , BuscariniE , QuarettiP , GarbagnatiF , SquassanteL , et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. American Journal of Roentgenology1996;167(3):759‐68. ">Rossi 1996</a>; <a href="./references#CD003046-bbs2-0093" title="RossiS , BuscariniE , GarbagnatiF , DiStasiM , QuarettiP , RagoM , et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. American Journal of Roentgenology1998;170(4):1015‐22. ">Rossi 1998</a>; <a href="./references#CD003046-bbs2-0045" title="AllgaierHP , DeibertP , ZuberI , OlschewskiM , BlumHE . Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet1999;353(9165):1676‐7. ">Allgaier 1999</a>; <a href="./references#CD003046-bbs2-0057" title="CurleySA , IzzoF , DelrioP , EllisLM , GranchiJ , ValloneP , et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Annals of Surgery1999;230(1):1‐8. ">Curley 1999</a>; <a href="./references#CD003046-bbs2-0064" title="FranciaG , MaroneG . Ultrasound guided percutaneous treatment of hepatocellular carcinoma by radiofrequency hyperthermia with 'cooled‐tip needle'. A preliminary clinical experience. European Journal of Ultrasound1999;9:145‐53. ">Francia 1999</a>; <a href="./references#CD003046-bbs2-0066" title="GoldbergSN , GazelleGS , MuellerPR . Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. American Journal of Roentgenology2000;174(2):323‐31. ">Goldberg 2000</a>; <a href="./references#CD003046-bbs2-0067" title="GrassoA , WatkinsonAF , TibballsJM , BurroughsAK . Radiofrequency ablation in the treatment of hepatocellular carcinoma ‐ a clinical viewpoint. Journal of Hepatology2000;33:667‐72. ">Grasso 2000</a>; <a href="./references#CD003046-bbs2-0076" title="LivraghiT , GoldbergSN , LazzaroniS , MeloniF , IeraceT , SolbiatiL , et al. Hepatocellular carcinoma: radio‐frequency ablation of medium and large lesions. Radiology2000;214(3):761‐8. ">Livraghi 2000</a>; <a href="./references#CD003046-bbs2-0087" title="NicoliN , CasarilA , MarchioriL , MangianteG , MariniG , ColombardiR . Intraoperative and percutaneous radiofrequency thermal ablation in the treatment of hepatocellular carcinoma. Chirurgia Italiana2000;52:29‐40. ">Nicoli 2000</a>). If necessary, the procedure can be repeated to treat larger lesions or patients with more than one liver tumour. </p> <p><i>Surgical resection</i> demands a radical resection of the tumours. This is often not feasible due to the impairment of liver function caused by the underlying cirrhosis. Local recurrence and de novo hepatocellular carcinoma at other locations within the liver are about 50% at three years and 70% at five years (<a href="./references#CD003046-bbs2-0046" title="AriiS , YamaokaY , FutagawaS , InoueK , KobayashiK , KojiroM , et al. Results of surgical and nonsurgical treatment for hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology2000;32:1224‐9. ">Arii 2000</a>; <a href="./references#CD003046-bbs2-0047" title="BismuthH , MajnoPE . Hepatobiliary surgery. Journal of Hepatology2000;32:208‐24. ">Bismuth 2000</a>; <a href="./references#CD003046-bbs2-0077" title="LlovetJM , SalaM , CastellsL , SuarezY , VilanaR , BianchiL , et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology2000;31:54‐8. ">Llovet 2000</a>). </p> <p><i>Orthotopic liver transplantation</i> is an alternative approach for selected patients with small hepatocellular carcinoma. The beneficial removal of liver cirrhosis as a predisposing factor for hepatocellular carcinoma is, however, often counterbalanced by progression of the tumour while the patient is waiting for a new organ. Moreover, organ shortage is a major factor limiting the availability of this procedure. The Milan criteria (one tumour of 5 cm or less in diameter, or three tumours with a diameter of 3 cm or less each) are the broadly accepted standard to identify patients suitable for liver transplantation (<a href="./references#CD003046-bbs2-0083" title="MazzaferroV , RegaliaE , DociR , AndreolaS , PulvirentiA , BozzettiF , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine1996;334:693‐9. ">Mazzaferro 1996</a>). Percutaneous techniques are used with increasing frequency to bridge the waiting time until transplantation (<a href="./references#CD003046-bbs2-0059" title="DubayDA , SandroussiC , KachuraJR , HoCS , BeecroftJR , VollmerCM , et al. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB2011;13(1):24‐32. ">Dubay 2011</a>). </p> <p><i>Medical treatment options</i>: Sorafenib, a multi‐kinase inhibitor improved median survival by 2.8 months in one trial (<a href="./references#CD003046-bbs2-0080" title="LlovetJM , RicciS , MazzaferroV , HilgardP , GaneE , BlancJF , et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine2008;359(4):378‐90. ">Llovet 2008</a>), and was approved for treatment of advanced hepatocellular carcinoma in 2007 (<a href="./references#CD003046-bbs2-0108" title="WörnsMA , WeinmannA , PfingstK , Schulte‐SasseC , MessowCM , Schulze‐BergkamenH , et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver disease. Journal of Clinical Gastroenterology2009;43(5):389‐90. ">Wörns 2009</a>). Sorafenib has not yet been compared to other interventions for hepatocellular carcinoma in randomised trials. </p> <p><i>Percutaneous ethanol injection (PEI)</i> causes dehydration and necrosis of tumour cells, accompanied by small vessel thrombosis, leading to tumour ischaemia and destruction. PEI is usually carried out under ultrasound guidance with repeated injections of ethanol on separate days. Best results for PEI are achieved in single hepatocellular carcinoma lesions of less than 3 cm in diameter, for which complete remission rates of 70% can be expected. Lower occurrences of complete remission have been observed in larger and multinodular tumours (<a href="./references#CD003046-bbs2-0075" title="LivraghiT , GiorgioA , MarinG , SalmiA , deSioI , BolodiL , et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long‐term results of percutaneous ethanol injection. Radiology1995;197(1):101‐8. ">Livraghi 1995</a>; <a href="./references#CD003046-bbs2-0074" title="LencioniR , PintoF , BassiAM , MorettiM , DiGiulioM , MarchiS , et al. Long‐term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: an European experience. European Radiology1997;7:514‐9. ">Lencioni 1997</a>). In one Cochrane review with meta‐analysis, we concluded that there was insufficient evidence to determine whether PEI or segmental liver resection was more effective (<a href="./references#CD003046-bbs2-0097" title="SchoppmeyerK , WeisS , MössnerJ , FleigWE . Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD006745.pub2] ">Schoppmeyer 2009</a>). In a recent up‐date of the <a href="./references#CD003046-bbs2-0097" title="SchoppmeyerK , WeisS , MössnerJ , FleigWE . Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD006745.pub2] ">Schoppmeyer 2009</a> review, no additional information could be added and there is little evidence to expect such evidence within the next years (<a href="./references#CD003046-bbs2-0104" title="WeisS , FrankeA , BergT , MössnerJ , FleigWE , SchoppmeyerK . Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database of Systematic Reviews2013; Vol. in press. ">Weis 2013</a>). </p> <p><i>Percutaneous acetic acid injection</i> (PAI) has been used as an alternative for ethanol in percutaneous treatment (<a href="./references#CD003046-bbs2-0088" title="OhnishiK , YoshiokaH , ItoS , FujiwaraK . Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology1998;27:67‐72. ">Ohnishi 1998</a>). Contraindications for PEI and PAI are cirrhosis with poor liver function (Child C cirrhosis), complete portal vein thrombosis, and massive ascites. We chose to analyse data from trials using PEI and PAI together because of the similarities between these two interventions in contrast to other treatment modalities. However, when results from individual trials are reported, we will report if PEI or PAI was used. In subgroup analysis, we will assess if there seems to be a difference in the overall survival in trials comparing RFA versus PEI or PAI. </p> <p><i>Other interventions</i>: Percutaneous cryoablation or interstitial laser photocoagulation are not yet routine clinical practice. </p> </section> <section id="CD003046-sec2-0003"> <h3 class="title" id="CD003046-sec2-0003">Why it is important to do this review</h3> <p>Treatment options of hepatocellular carcinoma have substantially increased since the introduction of ablation therapies in the 1990ies. While PEI was still the preferred treatment option at the beginning of the century (<a href="./references#CD003046-bbs2-0052" title="BruixJ , ShermanM , LlovetJM , BeaugrandM , LencioniR , BurroughsAK , et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona‐2000 EASL Conference. Journal of Hepatology2001;35:421‐30. ">Bruix 2001</a>), contradicting results have been reported in recently performed trials. Some were in favour of RFA (<a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>, while others showed no differences in the outcome between RFA and PEI (<a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>; <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>). In addition, the effects of RFA compared with hepatic resection for hepatocellular carcinoma are unclear. The current recommendations by the EASL and the EORTC are to use hepatic resection as a primary treatment and to use RFA when surgery is not possible (<a href="./references#CD003046-bbs2-0060" title="European Association for the Study of the Liver, European Organisation for Research and Treatment Of Cancer. EASL‐EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908‐43. ">EASL‐EORTC 2012</a>). As new trials have been published, we thought that this might change the evidence. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003046-sec1-0003" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003046-sec1-0003"></div> <p>To assess the beneficial and harmful effects of RFA versus placebo, no intervention, or any other therapeutic approach in patients with hepatocellular carcinoma. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003046-sec1-0004" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003046-sec1-0004"></div> <section id="CD003046-sec2-0004"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003046-sec3-0004"> <h4 class="title">Types of studies</h4> <p>We included randomised clinical trials, irrespective of publication status or blinding. We applied no language limitations. </p> </section> <section id="CD003046-sec3-0005"> <h4 class="title">Types of participants</h4> <p>All patients with hepatocellular carcinoma without contraindications for RFA (e.g. too many or too large tumours, extrahepatic malignant manifestation). </p> </section> <section id="CD003046-sec3-0006"> <h4 class="title">Types of interventions</h4> <p>RFA compared with placebo, no intervention, or any other intervention.</p> </section> <section id="CD003046-sec3-0007"> <h4 class="title">Types of outcome measures</h4> <section id="CD003046-sec4-0001"> <h5 class="title">Primary outcome</h5> <p> <ul id="CD003046-lst1-0002"> <li> <p>Overall survival.</p> </li> </ul> </p> </section> <section id="CD003046-sec4-0002"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003046-lst1-0003"> <li> <p>Two‐year survival.</p> </li> <li> <p>Event‐free survival concerning local recurrences, distant recurrence, de novo (a new) carcinoma, death. </p> </li> <li> <p>Local progression/recurrences.</p> </li> <li> <p>Frequency of complications/serious adverse events. Serious adverse events: Number of participants with serious adverse events defined as "any untoward medical occurrence that at any dose results in death, is life‐threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity". All other adverse events were be considered as non‐serious (<a href="./references#CD003046-bbs2-0069" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>). </p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Duration of hospital stay/health economics.</p> </li> </ul> </p> </section> </section> </section> <section id="CD003046-sec2-0005"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003046-sec3-0008"> <h4 class="title">Electronic searches</h4> <p>We performed electronic searches in the Cochrane Hepato‐Biliary Group Controlled Trials Register (<a href="./references#CD003046-bbs2-0065" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 3. Art. No.: LIVER. ">Gluud 2013</a>)<i>,</i> the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and ISI Web of Science (Science Citation Index Expanded) (<a href="./references#CD003046-bbs2-0094" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591‐603. ">Royle 2003</a>) to 3 September 2012. We did not update searches in CancerLit and Current Contents as well as searches of the journals (<i>Zeitschrift für Gastroenterologie</i> (suspended in 2000) and <i>Endoskopie Heute</i> (suspended in 1999). CancerLit is no longer updated and Current Contents has merged into ISI Web of Science. We used the search strategies with the time spans shown in <a href="./appendices#CD003046-sec2-0015">Appendix 1</a>, which ended September 2012. </p> </section> <section id="CD003046-sec3-0009"> <h4 class="title">Searching other resources  </h4> <p>We also handsearched proceedings of conferences of five oncological and hepatological societies (ASCO, ESMO, AASLD, EASL, APASL), as well as references of articles. We contacted researchers in the field and companies producing RFA equipment for information on further (unpublished) trials. </p> </section> </section> <section id="CD003046-sec2-0006"> <h3 class="title" id="CD003046-sec2-0006">Data collection and analysis</h3> <p>We performed this systematic review according to a peer‐reviewed, published protocol (<a href="./references#CD003046-bbs2-0110" title="GalandiD , AntesG . Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma [Protocol]. The Cochrane Library (Update Software, Oxford) 2001, Issue 2. ">Galandi 2001</a>), and followed the recommendations of The Cochrane Collaboration (<a href="./references#CD003046-bbs2-0068" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), and the Cochrane Hepato‐Biliary Group Module (<a href="./references#CD003046-bbs2-0065" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 3. Art. No.: LIVER. ">Gluud 2013</a>). We performed the analyses using Review Manager 5 (<a href="./references#CD003046-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). </p> <section id="CD003046-sec3-0010"> <h4 class="title">Selection of studies</h4> <p>One review author (SW) collected the publications of all trials potentially relevant for this review. Two review authors (SW, KS) independently selected trials for inclusion. </p> </section> <section id="CD003046-sec3-0011"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SW, AF) independently extracted the data from all trials. We included data from the first versions of the review by Galandi (<a href="./references#CD003046-bbs2-0111" title="GalandiD , AntesG . Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma [Review]. The Cochrane Library (Update Software, Oxford) 2002, Issue 3. ">Galandi 2002</a>; <a href="./references#CD003046-bbs2-0112" title="GalandiD , AntesG . Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews2004, Issue 2. [DOI: 10.1002/14651858.CD003046] ">Galandi 2004</a>). We contacted the principal authors of the trials to retrieve missing data. Where there were missing data for an appropriate judgement of the risk of bias, we judged the risk of bias as 'high'. We accepted the original trials' definitions for all beneficial and harmful outcomes although we attempted to extract information on all outcomes specified for this review. We resolved disagreements by discussion. We extracted type and number of serious adverse events, length of hospitalisation, and quality of life if available. </p> </section> <section id="CD003046-sec3-0012"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SW, KS) assessed the risk of bias of all trials included in this review, following the risk of bias domains, with definitions presented below (<a href="./references#CD003046-bbs2-0098" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association1995;273(5):408‐12. ">Schulz 1995;</a><a href="./references#CD003046-bbs2-0085" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. ">Moher 1998;</a><a href="./references#CD003046-bbs2-0072" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001;</a><a href="./references#CD003046-bbs2-0107" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336:601‐5. ">Wood 2008;</a><a href="./references#CD003046-bbs2-0081" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>; <a href="./references#CD003046-bbs2-0095" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1‐82. ">Savovic 2012</a>; <a href="./references#CD003046-bbs2-0096" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savovic 2012a</a>; <a href="./references#CD003046-bbs2-0065" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 3. Art. No.: LIVER. ">Gluud 2013</a>). </p> <section id="CD003046-sec4-0003"> <h5 class="title">Allocation sequence generation</h5> <p> <ul id="CD003046-lst1-0004"> <li> <p>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent research assistant not otherwise involved in the trial. </p> </li> <li> <p>Uncertain risk of bias: the method of sequence generation was not specified.</p> </li> <li> <p>High risk of bias: the sequence generation method was not random.</p> </li> </ul> </p> </section> <section id="CD003046-sec4-0004"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD003046-lst1-0005"> <li> <p>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g. if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes). </p> </li> <li> <p>Uncertain risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment. </p> </li> <li> <p>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants. </p> </li> </ul> </p> </section> <section id="CD003046-sec4-0005"> <h5 class="title">Blinding of participants, personnel, and outcome assessors</h5> <p> <ul id="CD003046-lst1-0006"> <li> <p>Low risk of bias: blinding was performed adequately, or the assessment of outcomes was not likely to be influenced by lack of blinding. </p> </li> <li> <p>Uncertain risk of bias: there was insufficient information to assess whether blinding was likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the assessment of outcomes were likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD003046-sec4-0006"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD003046-lst1-0007"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, had been employed to handle missing data. </p> </li> <li> <p>Uncertain risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> </section> <section id="CD003046-sec4-0007"> <h5 class="title">Selective outcome reporting</h5> <p> <ul id="CD003046-lst1-0008"> <li> <p>Low risk of bias: all outcomes were pre‐defined (e.g. in a published protocol) and reported, or all clinically relevant (e.g. overall survival, event‐free survival, or adverse events) were reported. </p> </li> <li> <p>Uncertain risk of bias: it was unclear whether all pre‐defined and clinically relevant outcomes were reported. </p> </li> <li> <p>High risk of bias: one or more clinically relevant outcomes were not reported, and data on these outcomes were likely to have been recorded. </p> </li> </ul> </p> </section> <section id="CD003046-sec4-0008"> <h5 class="title">Vested interest bias</h5> <p> <ul id="CD003046-lst1-0009"> <li> <p>Low risk of bias: the trial appeared to be free of other components (should be listed, e.g. industry bias, academic bias, etc.) that could put it at risk of bias. </p> </li> <li> <p>Uncertain risk of bias: it was unclear whether the trial was at risk of vested interest bias. </p> </li> <li> <p>High risk of bias: there were other factors in the trial that could put it at risk of bias (e.g. for‐profit involvement, study authors had conducted trials on the same topic, etc.). </p> </li> </ul> </p> </section> <section id="CD003046-sec4-0009"> <h5 class="title">Other bias</h5> <p> <ul id="CD003046-lst1-0010"> <li> <p>Low risk of bias: no other potential source of bias could be detected.</p> </li> <li> <p>Uncertain risk of bias: potential sources of bias could not be ruled out (e.g. missing outcome definition, unclear baseline differences, etc.). </p> </li> <li> <p>High risk of bias: other relevant sources of bias were present (e.g. small cohorts, significant baseline differences, etc.). </p> </li> </ul> </p> <p>A trial was considered with a low risk of bias, if it was assessed with low risk of bias in all of the specified bias risk domains, and a trial was considered with high risk of bias, if one or more of the specific domains were assessed to be unclear or with high risk of bias. </p> <p>We solved disagreements by discussion, or by contacting the Cochrane Hepato‐Biliary Group in Copenhagen. </p> </section> </section> <section id="CD003046-sec3-0013"> <h4 class="title">Units of analysis issues</h4> <p>We did not include cluster randomised trials. We did not expect or identify cross‐over trials due to the nature of the disease and the interventions investigated. We included trials with three or more treatment groups if pair‐wise comparison of a single intervention versus RFA was possible and if inclusion criteria of both intervention groups fulfilled the inclusion criteria. In order to exclude analysis bias by multiple counting of the shared intervention group, the shared intervention group was split into a corresponding number of subgroups with smaller sample size. We analysed and included each pair‐wise comparison separately. We measured two survival outcomes. We analysed recurrence‐free survival and overall survival separately. </p> </section> <section id="CD003046-sec3-0014"> <h4 class="title">Dealing with missing data</h4> <p>We considered missing data in the judgement of selective and incomplete reporting bias. In case of missing data that prevented trials from being included, we contacted trialists and requested missing data. In addition, we aimed to obtain hazard ratios (HRs) and standard deviations or Kaplan Meier survival plots for the survival outcome measures when these were not available from the original publication. </p> </section> <section id="CD003046-sec3-0015"> <h4 class="title">Assessment of heterogeneity  </h4> <p>We performed analyses of heterogeneity between trials by calculating the Chi<sup>2</sup> statistic using Review Manager 5 (<a href="./references#CD003046-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). In addition, we assessed heterogeneity by calculating the I<sup>2</sup> statistic (<a href="./references#CD003046-bbs2-0068" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), measuring the inconsistency among the trials and describing the percentage of variability in effect estimates that occurred due to heterogeneity rather than chance. For I<sup>2</sup> statistics, the following thresholds were applied: 0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity. </p> </section> <section id="CD003046-sec3-0016"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to do funnel plots if more than 10 trials were identified to give an overview regarding potential reporting bias and other bias sources (<a href="./references#CD003046-bbs2-0068" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD003046-sec3-0017"> <h4 class="title">Data synthesis</h4> <section id="CD003046-sec4-0010"> <h5 class="title">Meta‐analysis</h5> <p>We performed the meta‐analyses according to the recommendations of The Cochrane Collaboration (<a href="./references#CD003046-bbs2-0068" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), and the Cochrane Hepato‐Biliary Group Module<i>(</i><a href="./references#CD003046-bbs2-0065" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 3. Art. No.: LIVER. ">Gluud 2013</a><i>)</i>. We extracted HRs as relevant effect measures for overall survival, two‐year survival, event‐free survival, and local recurrences with 95% confidence intervals (CI) from publications. Alternatively, we estimated HRs from log rank Chi<sup>2</sup> statistics, log rank P values and given (total or group‐wise) numbers of events, observed‐to‐expected event ratios, or Kaplan‐Meier curves with patients at risk given, using methods presented by <a href="./references#CD003046-bbs2-0082" title="MachinD , StenningSP , ParmarMK , FayersPM , GirlingDJ , StephensRJ , et al. Thirty years of Medical Research Council randomized trials in solid tumours. Clinical Oncology1997;9:100‐14. ">Machin 1997</a> and <a href="./references#CD003046-bbs2-0090" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmer 1998</a>. In addition, we calculated risk ratios (RR) together with their 95% CIs for survival. We used odds ratios (OR) together with their 95% CIs to characterise effect differences between RFA and other interventions regarding dichotomous outcomes such as complication rates and the inverse‐variance method for measures on metric scale according to the protocol. </p> <p>We assigned trials to subcategories according to their type of control intervention. We presented pooled effects within each subcategory and as overall estimate of effects. We analysed trials comparing RFA versus two other interventions within a three‐armed design in that both comparisons were included independently within the respective subcategory using the given ‐ or estimated ‐ effect differences. The sample size or events or both, observed in the RFA group, allowed only once for the overall analysis to maintain the total sample sizes or events. </p> <p>We used random‐effects models to analyse the effect sizes (<a href="./references#CD003046-bbs2-0058" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). In comparison to fixed‐effect model meta‐analyses, these are more conservative and result in wider CIs of the meta‐analysed effect estimates, in order to avoid over‐optimistic significances. In contrast, random‐effects models put too much weight on small trials (which are often more biased). Therefore, we also conducted fixed‐effect model meta‐analysis and reported results from both models if the results differed. In the absence of relevant heterogeneity, both models will result in nearly identical effect estimations. </p> <p>For all available outcomes, we presented data tables or forest plots. The risk of bias within the trials was considered a potential source of heterogeneity, and, therefore, it was assessed in detail according to the methodology described above. We intended to perform a subgroup analysis to compare trials with low risk of bias with the overall evidence received from all suitable trials. </p> <p>We performed statistical analyses using Review Manager 5 Software (<a href="./references#CD003046-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). </p> </section> <section id="CD003046-sec4-0011"> <h5 class="title">Trial sequential analysis</h5> <p>We applied trial sequential analysis (<a href="./references#CD003046-bbs2-0056" title="Copenhagen Trial Unit. TSA ‐ trial sequential analysis, 2011. ctu.dk/tsa/ (accessed 16 December 2013). ">CTU 2011</a>; <a href="./references#CD003046-bbs2-0103" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for trial sequential analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 16 December 2013). ">Thorlund 2011</a>) because cumulative meta‐analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<a href="./references#CD003046-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61:64‐75. ">Wetterslev 2008</a>). To minimise random errors, we calculated the required information size (i.e. the number of participants needed in a meta‐analysis to detect or reject a certain intervention effect) (<a href="./references#CD003046-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61:64‐75. ">Wetterslev 2008</a>). The required information size calculation should also account for the heterogeneity or diversity present in the meta‐analysis (<a href="./references#CD003046-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61:64‐75. ">Wetterslev 2008</a>; <a href="./references#CD003046-bbs2-0106" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>). In our meta‐analysis, the required information size was based on the event proportion in the control group; assumption of a plausible RR reduction of 20%, or on the RR reduction observed in the included trials with low risk of bias; a risk of type I error of 5%; a risk of type II error of 20%; and the assumed diversity of the meta‐analysis (<a href="./references#CD003046-bbs2-0050" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61:763‐9. ">Brok 2008</a>; <a href="./references#CD003046-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61:64‐75. ">Wetterslev 2008</a>; <a href="./references#CD003046-bbs2-0051" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. ">Brok 2009</a>; <a href="./references#CD003046-bbs2-0101" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses. International Journal of Epidemiology2009;38(1):276‐86. ">Thorlund 2009</a>, <a href="./references#CD003046-bbs2-0106" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD003046-bbs2-0102" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. ">Thorlund 2010</a>). The underlying assumption of trial sequential analysis was that testing for significance may be performed each time a new trial is added to the meta‐analysis. We have added the trials according to the year of publication, and if more than one trial has been published in a year, we added trials alphabetically according to the last name of the first author. Based on the required information size, we constructed trial sequential monitoring boundaries (<a href="./references#CD003046-bbs2-0050" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61:763‐9. ">Brok 2008</a>; <a href="./references#CD003046-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61:64‐75. ">Wetterslev 2008</a>; <a href="./references#CD003046-bbs2-0051" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. ">Brok 2009</a>; <a href="./references#CD003046-bbs2-0101" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses. International Journal of Epidemiology2009;38(1):276‐86. ">Thorlund 2009</a>; <a href="./references#CD003046-bbs2-0106" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD003046-bbs2-0102" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. ">Thorlund 2010</a>). These boundaries determined the statistical inference one may draw regarding the cumulative meta‐analysis that has not reached the required information size; if the trial sequential monitoring boundaries were crossed before the required information size was reached, firm evidence may perhaps be established and further trials may turn out to be superfluous. In contrast, if the boundaries were not surpassed, it was most probably necessary to continue doing trials in order to detect or reject a certain intervention effect if the trial sequential monitoring boundaries for futility were not crossed. If the latter was the case, futility could be declared (<a href="./references#CD003046-bbs2-0050" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61:763‐9. ">Brok 2008</a>; <a href="./references#CD003046-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61:64‐75. ">Wetterslev 2008</a>; <a href="./references#CD003046-bbs2-0051" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. ">Brok 2009</a>; <a href="./references#CD003046-bbs2-0101" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses. International Journal of Epidemiology2009;38(1):276‐86. ">Thorlund 2009</a>; <a href="./references#CD003046-bbs2-0106" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>; <a href="./references#CD003046-bbs2-0102" title="ThorlundK , AnemaA , MillsE . Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology2010;2:57‐66. ">Thorlund 2010</a>). </p> </section> </section> <section id="CD003046-sec3-0018"> <h4 class="title">Summary of findings tables</h4> <p>We summarised the evidence in the 'Summary of findings' tables using GRADEpro (<a href="http://ims.cochrane.org/revman/other-resources/gradepro" target="_blank">ims.cochrane.org/revman/other‐resources/gradepro</a>). We used the GRADE classification in order to judge the quality of evidence. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003046-sec1-0005" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003046-sec1-0005"></div> <section id="CD003046-sec2-0007"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD003046-sec2-0018" title="">Characteristics of included studies</a>; <a href="./references#CD003046-sec2-0019" title="">Characteristics of excluded studies</a>. </p> <section id="CD003046-sec3-0019"> <h4 class="title">Results of the search</h4> <p>Our literature search revealed 2008 references. We removed 718 duplicates. From the remaining 1290 references, we identified 11 randomised clinical trials that fulfilled our inclusion criteria (<a href="./references#CD003046-sec2-0018" title="">Characteristics of included studies</a>). We identified no additional trials from other sources. Two trials still await classification with insufficient information that were reported in meeting abstracts available to date and with no additional information from the study authors (<a href="./references#CD003046-bbs2-0041" title="DiCostanzoGG , TortoraR , D'AdamoG , Galeota LanzaA , CarannanteN , LampasiF , et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma: a randomized controlled trial. Journal of Hepatology2011;54(Suppl 1):S254‐S255. ">Di Costanzo 2011</a>; <a href="./references#CD003046-bbs2-0042" title="KuanshengM , FengK , YanJ , WangS , BieP . A randomized controlled study of radiofrequency ablation and surgical resection for early‐stage hepatocellular carcinomas less than 4 cm in diameter. Hepatology2011;54(S1):418A. ">Kuansheng 2011</a>; <a href="./references#CD003046-sec2-0020" title="">Characteristics of studies awaiting classification</a>). One trial was still ongoing (<a href="./references#CD003046-bbs2-0043" title="NCT00814242 . Hepatectomy versus radiofrequency ablation for hepatocellular carcinoma adjacent to major blood vessels. clinicaltrials.gov/ct2/show/NCT00814242 (accessed 16 December 2013). ">NCT00814242</a>; <a href="./references#CD003046-sec2-0021" title="">Characteristics of ongoing studies</a>). We excluded 23 studies due to insufficient design or lack of relevant information (<a href="#CD003046-fig-0001">Figure 1</a>; <a href="./references#CD003046-sec2-0019" title="">Characteristics of excluded studies</a>). </p> <div class="figure" id="CD003046-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram of the literature search as well as number and reasons of excluded studies." data-id="CD003046-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram of the literature search as well as number and reasons of excluded studies. </p> </div> </div> </div> </section> <section id="CD003046-sec3-0020"> <h4 class="title">Included studies</h4> <p>We included and analysed 11 trials in this review. The trials included 1819 randomised participants. We found no trials comparing RFA versus placebo, no intervention, chemotherapy, or liver transplantation. </p> <p>Three trials with 578 participants compared RFA versus hepatic resection (<a href="./references#CD003046-bbs2-0002" title="ChenMS , LiJQ , ZhengY , GoRP , LiangHH , ZhangYQ , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery2006;243(3):321‐8. ">Chen 2006</a>; <a href="./references#CD003046-bbs2-0006" title="HuangJ , YanL , ChengZ , WuH , DuL , WangJ , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Annals of Surgery2010;252(6):903‐12. ">Huang 2010</a>; <a href="./references#CD003046-bbs2-0003" title="FengK , YanJ , LiX , MaK , WangS , BieP , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology2012;57(4):794‐802. ">Feng 2012</a>). </p> <p>Six trials with 1088 participants compared RFA versus PEI (<a href="./references#CD003046-bbs2-0007" title="LencioniR , AllgaierHP , CioniD , OlschewskiM , DeibertP , CrocettiL , et al. Small hepatocellular carcinoma: randomized comparison of radio‐frequency thermal ablation and percutaneous ethanol injection. Radiology2003;228:235‐40. ">Lencioni 2003</a>; <a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a>; <a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>; <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>). Two of the trials with 344 participants randomised participants to three intervention groups (<a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0009" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI‐hd)</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0010" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PAI)</a>). In one trial, RFA was compared with a standard dose of PEI (<a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>), and versus a high dose of PEI (<a href="./references#CD003046-bbs2-0009" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI‐hd)</a>). In the other trial, RFA was compared with PEI (<a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>) and versus PAI (<a href="./references#CD003046-bbs2-0010" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PAI)</a>). </p> <p>One trial each compared RFA versus microwave ablation (n = 72 participants) (<a href="./references#CD003046-bbs2-0012" title="ShibataT , IimuroY , YamamotoY , MaetaniY , AmetaniF , ItohK , et al. Small hepatocellular carcinoma: comparison of radio‐frequency ablation and percutaneous microwave coagulation therapy. Radiology2002;223:331‐7. ">Shibata 2002</a>) and versus laser ablation (n = 81 participants) (<a href="./references#CD003046-bbs2-0004" title="FerrariFS , MgliolaA , ScorzelliA , StellaA , VigniF , DrudiFM , et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long‐term results. La Radiologia Medica2007;112(3):377‐93. ">Ferrari 2007</a>). </p> <p>Regarding the comparison of RFA versus other interventions, 10 out of 11 comparisons (including also the two three‐armed trials) reported on the primary outcome, overall survival (<a href="./references#CD003046-fig-00101" title="">Analysis 1.1</a>). Two‐year survival could be extracted from seven trials (with nine comparisons) (<a href="./references#CD003046-fig-00201" title="">Analysis 2.1</a>). Data on event‐free survival were available from eight trials and on local progression were available from six trials (<a href="./references#CD003046-fig-00301" title="">Analysis 3.1</a>; <a href="./references#CD003046-fig-00401" title="">Analysis 4.1</a>). Rates of major complications or procedure‐related deaths, or both, were reported in all trials. </p> </section> <section id="CD003046-sec3-0021"> <h4 class="title">Excluded studies</h4> <p>Reasons for excluding identified studies were as follows: one trial compared RFA alone with RFA plus hepatic arterial occlusion (<a href="./references#CD003046-bbs2-0027" title="KobayashiM , IkedaK , KawamuraY , HosakaT , SezakiH , YatsujiH , et al. Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma‐direct ablative effects and a long‐term outcome. Liver International2007;27(3):353‐9. ">Kobayashi 2007</a>), one with RFA plus PEI (<a href="./references#CD003046-bbs2-0040" title="ZhangYJ , LiangHH , ChenMS , GuoRP , LiJQ , ZhengY , et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology2007;244(2):599‐607. ">Zhang 2007</a>), and two with RFA plus transarterial chemo‐embolisation (TACE) (<a href="./references#CD003046-bbs2-0031" title="MorimotoM , NumataK , KondouM , NozakiA , MoritaS , TanakaK . Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer2010;116(23):5452‐60. ">Morimoto 2010</a>; <a href="./references#CD003046-bbs2-0032" title="MorimotoM , NumataK , KondoM , NozakiA , MoriyaS , TakizawaK , et al. Long‐term outcome in patients with intermediate‐sized hepatocellular carcinoma: a randomized controlled trial to determine the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Hepatology2011;54(Suppl S1):1366A. ">Morimoto 2011</a>). Ten studies were not randomised clinical trials (<a href="./references#CD003046-bbs2-0016" title="BuscariniL , DiStasiM , BuscariniE , FornariF , SquassanteL , RossiS , et al. Clinical presentation, diagnostic work‐up and therapeutic choices in two consecutive series of patients with hepatocellular carcinoma. Oncology1996;53(3):204‐9. ">Buscarini 1996</a>; <a href="./references#CD003046-bbs2-0023" title="GoldbergSN , HahnPF , TanabeKK , MuellerPR , SchimaW , AthanasoulisCA , et al. Percutaneous radiofrequency tissue ablation: does perfusion‐mediated tissue cooling limit coagulation necrosis?. Journal of Vascular &amp; Interventional Radiology1998;9(1):101‐11. ">Goldberg 1998</a>; <a href="./references#CD003046-bbs2-0020" title="CuschieriA , BrackenJ , BoniL . Initial experience with laparoscopic ultrasound‐guided radiofrequency thermal ablation of hepatic tumours. Endoscopy1999;31(4):318‐21. ">Cuschieri 1999</a>; <a href="./references#CD003046-bbs2-0025" title="JiaoLR , HansenPD , HavlikR , MitryRR , PignatelliM , HabibN . Clinical short‐term results of radiofrequency ablation in primary and secondary liver tumors. American Journal of Surgery1999;177(4):303‐6. ">Jiao 1999</a>; <a href="./references#CD003046-bbs2-0029" title="LivraghiT , GoldbergSN , LazzaroniS , MeloniF , SolbiatiL , GazelleGS . Small hepatocellular carcinoma: treatment with radio‐frequency ablation versus ethanol injection. Radiology1999;210(3):655‐61. ">Livraghi 1999</a>; <a href="./references#CD003046-bbs2-0028" title="KurokohchiK , WatanabeS , MasakiT , HosomiN , HimotoT , KimuraY , et al. Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma. World Journal of Gastroenterology2005;11(10):1426‐32. ">Kurokohchi 2005</a>; <a href="./references#CD003046-bbs2-0039" title="ZhangFJ , WuPH , ZhaoM , GuYK , ZhangL , TanZB . Evaluation of combined percutaneous radio‐frequency ablation and percutaneous ethanol injection after transcatheter arterial chemoembolization for hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi2005;27(4):248‐50. ">Zhang 2005</a>; <a href="./references#CD003046-bbs2-0030" title="LüMD , KuangM , LiangLJ , XieXY , PengBG , LiuGJ , et al. Surgical resection versus percutaneous thermal ablation for early‐stage hepatocellular carcinoma: a randomized clinical trial. National Medical Journal of China2006;86(12):801‐5. ">Lü 2006</a>; <a href="./references#CD003046-bbs2-0026" title="KhanMR , PoonRTP , NgKK , ChanACC , YuenJ , TungH , et al. Comparison of percutaneous and surgical approaches for radiofrequency ablation of small and medium hepatocellular carcinoma. Archives of Surgery2007;142(12):1136‐43. ">Khan 2007</a>; <a href="./references#CD003046-bbs2-0033" title="OhmotoK , YoshiokaN , TomiyamaY , ShibataN , KawaseT , YoshidaK , et al. Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. Journal of Gastroenterology and Hepatology2009;24:223‐7. ">Ohmoto 2009</a>). Five studies were retrospective cohort studies (<a href="./references#CD003046-bbs2-0015" title="AmarnathS , GriffithKA , HigginsE , LawrenceTS , RubinJ , PanCC . Comparison of patients with hepatocellular carcinoma (HCC) treated with external beam radiotherapy (EBRT) or radiofrequency ablation (RFA). International Journal of Radiation Oncology, Biology, Physics2006;66(3 Suppl):1071. ">Amarnath 2006</a>; <a href="./references#CD003046-bbs2-0038" title="UenoS , SakodaM , KuboF , HiwatashiK , TatenoT , BabaY , et al. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. Journal of Hepato‐Biliary‐Pancreatic Surgery2009;16:359‐66. ">Ueno 2009</a>; <a href="./references#CD003046-bbs2-0034" title="OpocherE , BarabinoM , CostaM , ZuinM , CarnevaliP , SantambrogioR . The impact of radiofrequency ablation and liver resection on patients with cirrhosis and early and very early hepatocellular carcinoma. HPB2010;12(Suppl S1):69. ">Opocher 2010</a>; <a href="./references#CD003046-bbs2-0037" title="SreenivasanK , RoyS , SubramaniamM . Comparison of radiofrequency ablation versus resection for the treatment of hepatocellular carcinoma. HPB2010;12(Suppl S1):164. ">Sreenivasan 2010</a>; <a href="./references#CD003046-bbs2-0024" title="GoryI , FinkM , BellS , GowP , NicollA , KnightV , et al. Radiofrequency ablation versus surgical resection for the treatment of early stage hepatocellular carcinoma (HCC) ‐ a large multicentre study. Journal of Hepatology2012;56(Suppl 2):S392‐S393. ">Gory 2012</a>). One publication was retracted (<a href="./references#CD003046-bbs2-0018" title="ChengBQ , JiaCQ , LiuCT , FanW , WangQL , ZhangZL , et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. Journal of the American Medical Association2008;299(14):1669‐77. ">Cheng 2008</a>). One study did not include patient data but was a Markov model analysis (<a href="./references#CD003046-bbs2-0019" title="ChoYK , KimJK , KimWT , ChungJW . Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology2010;51(4):1116‐8. ">Cho 2010</a>). Akamatsu et al switched patients from PEI to RFA during the study (<a href="./references#CD003046-bbs2-0014" title="AkamatsuM , YoshidaH , ObiS , SatoS , KoikeY , FujishimaT , et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver International2004;24(6):625‐9. ">Akamatsu 2004</a>). It was unclear whether randomisation was performed in two trials (<a href="./references#CD003046-bbs2-0021" title="GanYH , YieSH , RenZG , XiaJL , ZhangBH , WangYH , et al. Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma. Chinese Journal of Oncology2004;26(8):496‐8. ">Gan 2004</a>; <a href="./references#CD003046-bbs2-0017" title="ChenMS , ZhangYJ , LiJQ , LiangHH , ZhangYQ , ZhengY . Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency alone for small hepatocellular carcinoma. Chinese Journal of Oncology2005;27(10):623‐5. ">Chen 2005</a>). We contacted the study authors but they did not reply and, therefore, we did not include the trials (<a href="./references#CD003046-bbs2-0021" title="GanYH , YieSH , RenZG , XiaJL , ZhangBH , WangYH , et al. Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma. Chinese Journal of Oncology2004;26(8):496‐8. ">Gan 2004</a>; <a href="./references#CD003046-bbs2-0017" title="ChenMS , ZhangYJ , LiJQ , LiangHH , ZhangYQ , ZhengY . Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency alone for small hepatocellular carcinoma. Chinese Journal of Oncology2005;27(10):623‐5. ">Chen 2005</a>). RFA was also used to treat portal vein thrombosis in one study and, therefore, the effects of RFA on tumour growth could not be extracted (<a href="./references#CD003046-bbs2-0022" title="GiorgioA , FarellaN , DiSarnoA , ScognamiglioU , DeStefanoG , DeRogatisA , et al. Western trial comparing percutaneous radiofrequency of both hepatocellular carcinoma and the portal venous tumor thrombus plus sorafenib with sorafenib alone. Journal of Hepatology2011;54(Suppl 1):S542. ">Giorgio 2011a</a>). Peng et al only included patients with recurrent hepatocellular carcinoma. As this cohort displays differences to patients with newly diagnosed hepatocellular carcinoma, we did not include this trial (<a href="./references#CD003046-bbs2-0035" title="PengZW , ZhangYJ , LiangHH , LinXJ , GuoRP , ChenM . Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology2012;262(2):689‐700. ">Peng 2012</a>). One trial used laparoscopic RFA and was excluded (<a href="./references#CD003046-bbs2-0036" title='SantambrogioR , KlugerM , CostaM , BelliA , LaurentA , ZuinM , et al. Hepatic resection versus laparoscopic radiofrequency ablation for "very early" hepatocellular carcinoma. Digestive and Liver Disease2012;44(Suppl 1):S9‐S10. '>Santambrogio 2012</a>). </p> </section> </section> <section id="CD003046-sec2-0008"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, risk of bias was low in six trials and high in five trials. We only included the low risk of bias trials in the subgroup analysis. </p> <section id="CD003046-sec3-0022"> <h4 class="title">Allocation</h4> <section id="CD003046-sec4-0012"> <h5 class="title">Generation of allocation sequence and allocation concealment</h5> <p>Allocation generation was done by a computer in seven trials, by random numbers in three trials (<a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a>; <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>; <a href="./references#CD003046-bbs2-0003" title="FengK , YanJ , LiX , MaK , WangS , BieP , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology2012;57(4):794‐802. ">Feng 2012</a>), and the method of the allocation generation was not reported in one trial (<a href="./references#CD003046-bbs2-0012" title="ShibataT , IimuroY , YamamotoY , MaetaniY , AmetaniF , ItohK , et al. Small hepatocellular carcinoma: comparison of radio‐frequency ablation and percutaneous microwave coagulation therapy. Radiology2002;223:331‐7. ">Shibata 2002</a>). The Shibata trial was described as a randomised trial. However, we were unable to obtain the missing information on allocation generation by the study authors. Concealed allocation was ensured by using a computer‐based procedure in six trials, by sealed envelopes in three trials (<a href="./references#CD003046-bbs2-0012" title="ShibataT , IimuroY , YamamotoY , MaetaniY , AmetaniF , ItohK , et al. Small hepatocellular carcinoma: comparison of radio‐frequency ablation and percutaneous microwave coagulation therapy. Radiology2002;223:331‐7. ">Shibata 2002</a>; <a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>; <a href="./references#CD003046-bbs2-0006" title="HuangJ , YanL , ChengZ , WuH , DuL , WangJ , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Annals of Surgery2010;252(6):903‐12. ">Huang 2010</a>), and by a coded list in one trial (<a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>). For the remaining trial, the study authors did not describe if allocation concealment was performed (<a href="./references#CD003046-bbs2-0004" title="FerrariFS , MgliolaA , ScorzelliA , StellaA , VigniF , DrudiFM , et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long‐term results. La Radiologia Medica2007;112(3):377‐93. ">Ferrari 2007</a>). </p> </section> </section> <section id="CD003046-sec3-0023"> <h4 class="title">Blinding</h4> <p>Our most important outcomes were survival and tumour recurrence, which are unlikely to be significantly influenced by lack of blinding of both participants and outcome assessors. Moreover, as treatment modalities such as RFA and hepatic resection differ substantially with regard to the degree of invasiveness, procedure performance, etc., reasonable blinding to the treatment of an investigator or an informed patient is unlikely. Objective outcomes such as adverse events were blinded in one trial only and, therefore, only this trial was judged as a low risk of bias trial (<a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>); all other trials had a high risk of bias (<a href="./references#CD003046-fig-00501" title="">Analysis 5.1</a>). </p> </section> <section id="CD003046-sec3-0024"> <h4 class="title">Incomplete outcome data</h4> <p>An intention‐to‐treat (ITT) analysis was explicitly stated in five trials (<a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a>; <a href="./references#CD003046-bbs2-0002" title="ChenMS , LiJQ , ZhengY , GoRP , LiangHH , ZhangYQ , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery2006;243(3):321‐8. ">Chen 2006</a>; <a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>; <a href="./references#CD003046-bbs2-0006" title="HuangJ , YanL , ChengZ , WuH , DuL , WangJ , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Annals of Surgery2010;252(6):903‐12. ">Huang 2010</a>; <a href="./references#CD003046-bbs2-0003" title="FengK , YanJ , LiX , MaK , WangS , BieP , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology2012;57(4):794‐802. ">Feng 2012</a>). Chen et al reported on 19 patients randomised to RFA who had later been subjected to resection (<a href="./references#CD003046-bbs2-0002" title="ChenMS , LiJQ , ZhengY , GoRP , LiangHH , ZhangYQ , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery2006;243(3):321‐8. ">Chen 2006</a>). These participants were excluded from the primary analysis. Results were adequately presented for both the ITT and the per‐protocol analysis. The ITT results were considered for the meta‐analysis of the data. Similarly, in <a href="./references#CD003046-bbs2-0006" title="HuangJ , YanL , ChengZ , WuH , DuL , WangJ , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Annals of Surgery2010;252(6):903‐12. ">Huang 2010</a>, seven patients were switched from RFA to the resection group on their own decision but were analysed according to ITT (used in this review) and per‐protocol. In two trials, it was unclear whether incomplete outcome data had been adequately addressed (<a href="./references#CD003046-bbs2-0012" title="ShibataT , IimuroY , YamamotoY , MaetaniY , AmetaniF , ItohK , et al. Small hepatocellular carcinoma: comparison of radio‐frequency ablation and percutaneous microwave coagulation therapy. Radiology2002;223:331‐7. ">Shibata 2002</a>; <a href="./references#CD003046-bbs2-0004" title="FerrariFS , MgliolaA , ScorzelliA , StellaA , VigniF , DrudiFM , et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long‐term results. La Radiologia Medica2007;112(3):377‐93. ">Ferrari 2007</a>). </p> </section> <section id="CD003046-sec3-0025"> <h4 class="title">Selective reporting</h4> <p>Ten trials were free of selective outcome reporting bias as the most relevant clinical outcome (overall survival was not reported in <a href="./references#CD003046-bbs2-0012" title="ShibataT , IimuroY , YamamotoY , MaetaniY , AmetaniF , ItohK , et al. Small hepatocellular carcinoma: comparison of radio‐frequency ablation and percutaneous microwave coagulation therapy. Radiology2002;223:331‐7. ">Shibata 2002</a>). The other 10 trials reported outcomes in a sufficiently detailed manner to allow estimations of HR based on Parmar's method (<a href="./references#CD003046-bbs2-0090" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmer 1998</a>). </p> <section id="CD003046-sec4-0013"> <h5 class="title">Vested interest bias</h5> <p>Relevant vested interest bias such as industry funding or relevant academic bias was unclear in two trials (<a href="./references#CD003046-bbs2-0004" title="FerrariFS , MgliolaA , ScorzelliA , StellaA , VigniF , DrudiFM , et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long‐term results. La Radiologia Medica2007;112(3):377‐93. ">Ferrari 2007</a>; <a href="./references#CD003046-bbs2-0012" title="ShibataT , IimuroY , YamamotoY , MaetaniY , AmetaniF , ItohK , et al. Small hepatocellular carcinoma: comparison of radio‐frequency ablation and percutaneous microwave coagulation therapy. Radiology2002;223:331‐7. ">Shibata 2002</a>), and not present in any of the trials as stated in the manuscript or directly by the study authors. Lin et al. performed two randomised clinical trials during the same time period. Patients were assigned to one of the trials according to their hospital admission week (<a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>) However, we judged this to have low risk of bias. </p> </section> <section id="CD003046-sec4-0014"> <h5 class="title">Other source of bias</h5> <p>Other sources of bias, namely possible premature stopping (<a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>), an unusual high number of patients switching groups (<a href="./references#CD003046-bbs2-0002" title="ChenMS , LiJQ , ZhengY , GoRP , LiangHH , ZhangYQ , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery2006;243(3):321‐8. ">Chen 2006</a>) or undefined outcomes (<a href="./references#CD003046-bbs2-0004" title="FerrariFS , MgliolaA , ScorzelliA , StellaA , VigniF , DrudiFM , et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long‐term results. La Radiologia Medica2007;112(3):377‐93. ">Ferrari 2007</a>) were present in three trials and we judged them to have an unclear risk of bias. </p> </section> <section id="CD003046-sec4-0015"> <h5 class="title">Overall bias risk assessment</h5> <p>Overall risk of bias was low in five trials and high in six trials (<a href="#CD003046-fig-0002">Figure 2</a>; <a href="#CD003046-fig-0003">Figure 3</a>). For a subgroup analysis, we only included low risk of bias trials. </p> <div class="figure" id="CD003046-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (survival outcomes)." data-id="CD003046-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (survival outcomes). </p> </div> </div> </div> <div class="figure" id="CD003046-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study (survival outcomes)." data-id="CD003046-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (survival outcomes). </p> </div> </div> </div> </section> </section> </section> <section id="CD003046-sec2-0009"> <h3 class="title" id="CD003046-sec2-0009">Effects of interventions</h3> <p>See: <a href="./full#CD003046-tbl-0001"><b>Summary of findings for the main comparison</b> Hepatic resection compared with radiofrequency ablation</a>; <a href="./full#CD003046-tbl-0002"><b>Summary of findings 2</b> Percutaneous ethanol injection compared with radiofrequency ablation for early hepatocellular carcinoma</a>; <a href="./full#CD003046-tbl-0003"><b>Summary of findings 3</b> Clinical characteristics of patients treated with radiofrequency ablation or percutaneous ethanol injection</a> </p> <section id="CD003046-sec3-0026"> <h4 class="title">Radiofrequency ablation versus hepatic resection</h4> <section id="CD003046-sec4-0016"> <h5 class="title">Comparison for efficacy outcomes</h5> <p>Three randomised clinical trials were identified that compared RFA versus hepatic resection (<a href="./references#CD003046-bbs2-0002" title="ChenMS , LiJQ , ZhengY , GoRP , LiangHH , ZhangYQ , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery2006;243(3):321‐8. ">Chen 2006</a>; <a href="./references#CD003046-bbs2-0006" title="HuangJ , YanL , ChengZ , WuH , DuL , WangJ , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Annals of Surgery2010;252(6):903‐12. ">Huang 2010</a>; <a href="./references#CD003046-bbs2-0003" title="FengK , YanJ , LiX , MaK , WangS , BieP , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology2012;57(4):794‐802. ">Feng 2012</a>), of which two had low risk of bias (<a href="./references#CD003046-bbs2-0006" title="HuangJ , YanL , ChengZ , WuH , DuL , WangJ , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Annals of Surgery2010;252(6):903‐12. ">Huang 2010</a>; <a href="./references#CD003046-bbs2-0003" title="FengK , YanJ , LiX , MaK , WangS , BieP , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology2012;57(4):794‐802. ">Feng 2012</a>), and one had high risk of bias (<a href="./references#CD003046-bbs2-0002" title="ChenMS , LiJQ , ZhengY , GoRP , LiangHH , ZhangYQ , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery2006;243(3):321‐8. ">Chen 2006</a>). Analysing the results from all three trials using a random‐effects model showed no significant difference between the compared interventions regarding overall survival (HR 0.71; 95% CI 0.44 to 1.15) (<a href="./references#CD003046-fig-00101" title="">Analysis 1.1</a>) and two‐year survival (HR 0.51; 95% CI 0.24 to 1.08) (<a href="./references#CD003046-fig-00201" title="">Analysis 2.1</a>). Meta‐analysis using a fixed‐effect model showed a result in favour of hepatic resection compared with RFA on overall survival (HR 0.76; 95% CI 0.58 to 1.00) (<a href="./references#CD003046-fig-00102" title="">Analysis 1.2</a>). In addition to the calculation of the HR, dichotomous outcomes on overall survival could be extracted from the two trials with low risk of bias (<a href="./references#CD003046-bbs2-0006" title="HuangJ , YanL , ChengZ , WuH , DuL , WangJ , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Annals of Surgery2010;252(6):903‐12. ">Huang 2010</a>; <a href="./references#CD003046-bbs2-0003" title="FengK , YanJ , LiX , MaK , WangS , BieP , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology2012;57(4):794‐802. ">Feng 2012</a>; <a href="./references#CD003046-fig-00103" title="">Analysis 1.3</a>). In concordance with the HR analysis, resection yielded statistically significant improved survival both using the fixed‐effect and random‐effects model meta‐analyses (RR fixed 0.61; 95% CI 0.44 to 0.82 and RR random 0.60; 95% CI 0.44 to 0.82). </p> <section id="CD003046-sec5-0001"> <h6 class="title">Trial sequential analysis</h6> <p>Heterogeneity was present (I<sup>2</sup> = 67%, P value = 0.05). The diversity‐adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the resection group; a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. This diversity may be an underestimation of the diversity of both the present and future meta‐analyses, but has the advantage of narrowing the distance between the accrued and the required information size. Trial sequential analysis was only possible for two trials (<a href="./references#CD003046-bbs2-0006" title="HuangJ , YanL , ChengZ , WuH , DuL , WangJ , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Annals of Surgery2010;252(6):903‐12. ">Huang 2010</a>; <a href="./references#CD003046-bbs2-0003" title="FengK , YanJ , LiX , MaK , WangS , BieP , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology2012;57(4):794‐802. ">Feng 2012</a>), as we could not calculate dichotomous outcomes for the third trial (<a href="./references#CD003046-bbs2-0002" title="ChenMS , LiJQ , ZhengY , GoRP , LiangHH , ZhangYQ , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery2006;243(3):321‐8. ">Chen 2006</a>). Calculating the number of patients needed in order to judge an RRR of 20%, 2455 participants would need to be recruited. Even with the patients of the third trial, only 578 patients were randomised to RFA versus resection. Therefore, no firm evidence for benefit or harm has been reached yet (<a href="#CD003046-fig-0004">Figure 4</a>). As can be seen from the figure, the cumulative Z‐score did not cross the trial sequential monitoring boundaries and did reach the area of futility. </p> <div class="figure" id="CD003046-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial sequential analysis for the comparison radiofrequency ablation versus hepatic resection on mortality in patients with hepatocellular carcinoma. The diversity‐adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the percutaneous ethanol injection group (PEI); a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. The cumulative Z‐score never crossed the alpha‐spending monitoring boundary for harm and did not reach the beta‐spending monitoring boundaries (the area of futility), which was not even drawn by the program. Therefore, further randomised trials are needed." data-id="CD003046-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial sequential analysis for the comparison radiofrequency ablation versus hepatic resection on mortality in patients with hepatocellular carcinoma.</b> </p> <p>The diversity‐adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the percutaneous ethanol injection group (PEI); a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. The cumulative Z‐score never crossed the alpha‐spending monitoring boundary for harm and did not reach the beta‐spending monitoring boundaries (the area of futility), which was not even drawn by the program. Therefore, further randomised trials are needed. </p> </div> </div> </div> </section> <section id="CD003046-sec5-0002"> <h6 class="title">Subgroup analysis</h6> <p>In a subgroup analysis that included low‐risk of bias trials only, results indicated that hepatic resection yields better results than RFA regarding overall survival (HR 0.56; 95% CI 0.40 to 0.78) (<a href="./references#CD003046-fig-00103" title="">Analysis 1.3</a>) and two‐year survival (HR 0.38; 95% CI 0.17 to 0.84) (<a href="./references#CD003046-fig-00202" title="">Analysis 2.2</a>). Regarding event‐free survival, the results indicated that hepatic resection seemed better than RFA (HR 0.70; 95% CI 0.54 to 0.91) (<a href="./references#CD003046-fig-00301" title="">Analysis 3.1</a>). Only one trial reported on local progression and found hepatic resection was superior to RFA (HR 0.48; 95% CI 0.28 to 0.82) (<a href="./references#CD003046-fig-00401" title="">Analysis 4.1</a>). </p> </section> </section> <section id="CD003046-sec4-0017"> <h5 class="title">Comparison for safety outcomes</h5> <p>Major complications (including one procedure‐related death) were only reported in 55% of patients in the surgery arm of one trial (OR 8.24; 95% CI 2.12 to 31.95) (<a href="./references#CD003046-fig-00501" title="">Analysis 5.1</a>) (<a href="./references#CD003046-bbs2-0002" title="ChenMS , LiJQ , ZhengY , GoRP , LiangHH , ZhangYQ , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery2006;243(3):321‐8. ">Chen 2006</a>). </p> </section> <section id="CD003046-sec4-0018"> <h5 class="title">Comparison for economic outcomes</h5> <p>Our results show that RFA was associated with shorter duration of hospital stay compared with surgery (standardised mean difference 2.18 days; 95% CI 1.97 to 2.39). </p> </section> </section> <section id="CD003046-sec3-0027"> <h4 class="title">Radiofrequency ablation versus percutaneous ethanol injection/percutaneous acetic acid injection </h4> <section id="CD003046-sec4-0019"> <h5 class="title">Comparison for efficacy outcomes</h5> <p>Six trials compared RFA with PEI of which four had a low risk of bias (<a href="./references#CD003046-bbs2-0007" title="LencioniR , AllgaierHP , CioniD , OlschewskiM , DeibertP , CrocettiL , et al. Small hepatocellular carcinoma: randomized comparison of radio‐frequency thermal ablation and percutaneous ethanol injection. Radiology2003;228:235‐40. ">Lencioni 2003</a>; <a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a>) and two had a high risk of bias (<a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>; <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>). The overall effects of RFA seemed superior to PEI regarding overall survival (HR 1.64; 95% CI 1.31 to 2.07) (<a href="./references#CD003046-fig-00101" title="">Analysis 1.1</a>), two‐year survival (HR 1.82; 95% CI 1.34 to 2.47) (<a href="./references#CD003046-fig-00201" title="">Analysis 2.1</a>), event‐free survival (HR 1.55; 95% CI 1.31 to 1.85) (<a href="./references#CD003046-fig-00301" title="">Analysis 3.1</a>), and local progression (HR 2.44; 95% CI 1.71 to 3.49) (<a href="./references#CD003046-fig-00401" title="">Analysis 4.1</a>). No significant difference was found if only the result from the four trials with low risk of bias were meta‐analysed (overall survival: HR 1.19; 95% CI 0.79 to 1.77). One trial compared the two interventions for single and very small (2 cm or less) hepatocellular carcinoma and found no differences in overall survival (<a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>) (<a href="./full#CD003046-tbl-0002">summary of findings Table 2</a>). </p> <p>In addition to the calculation of the HR, dichotomous outcomes (RR) on overall survival were calculated from all six trials. There was no significant difference between the RFA group versus the PEI/PAI group (RR 1.76; 95% CI 0.97 to 3.22) (<a href="./references#CD003046-fig-00601" title="">Analysis 6.1</a>). </p> <p>In addition, a subgroup analysis was performed in order to compare the results for overall survival of RFA versus PEI and RFA versus PAI. RFA versus PAI was only investigated in one three‐armed trial (<a href="./references#CD003046-bbs2-0010" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PAI)</a>), as compared to the six trials that investigated RFA versus PEI (<a href="./references#CD003046-bbs2-0007" title="LencioniR , AllgaierHP , CioniD , OlschewskiM , DeibertP , CrocettiL , et al. Small hepatocellular carcinoma: randomized comparison of radio‐frequency thermal ablation and percutaneous ethanol injection. Radiology2003;228:235‐40. ">Lencioni 2003</a>; <a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>; <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>). In a test of subgroup differences, we found no significant difference between the effect of RFA versus PEI or PAI (P value = 0.75) (<a href="./references#CD003046-fig-00105" title="">Analysis 1.5</a>). The body of evidence was not changed if the comparison of RFA versus PAI was excluded (<a href="./references#CD003046-fig-00105" title="">Analysis 1.5</a>; <a href="./references#CD003046-fig-00502" title="">Analysis 5.2</a>; <a href="./references#CD003046-fig-00505" title="">Analysis 5.5</a>). </p> <section id="CD003046-sec5-0003"> <h6 class="title">Trial sequential analysis on overall mortality</h6> <p>Heterogeneity was not detected (I<sup>2</sup> = 0%, P value = 0.70). The DARIS was calculated based upon a proportion of deaths of 30% in the PEI group; an RRR of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. Trial sequential analysis with data from six trials that compared RFA with PEI found that only 986 patients of the DARIS of 2455 were accrued (40.2%) in order to obtain a risk reduction of 20%. As can be seen, the cumulative Z‐score did not cross the trial sequential monitoring boundaries for benefit, harm, or futility (<a href="#CD003046-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD003046-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial sequential analysis for the comparison radiofrequency ablation versus percutaneous ethanol injection group (PEI) on mortality in patients with hepatocellular carcinoma.     The diversity‐adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the PEI group; a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. As it can be seen, the cumulative Z‐score has never crossed the alpha‐spending monitoring boundary for benefit and has not reached the beta‐spending monitoring boundary (the area of futility). Therefore, further randomised trials are needed." data-id="CD003046-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial sequential analysis for the comparison radiofrequency ablation versus percutaneous ethanol injection group (PEI) on mortality in patients with hepatocellular carcinoma.</b> <br/> <br/> The diversity‐adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the PEI group; a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. As it can be seen, the cumulative Z‐score has never crossed the alpha‐spending monitoring boundary for benefit and has not reached the beta‐spending monitoring boundary (the area of futility). Therefore, further randomised trials are needed. </p> </div> </div> </div> </section> <section id="CD003046-sec5-0004"> <h6 class="title">Subgroup analysis</h6> <p>A subgroup analysis including low‐risk of bias trials only, was performed for all comparisons, but it did not change the body of evidence (<a href="./references#CD003046-fig-00203" title="">Analysis 2.3</a>; <a href="./references#CD003046-fig-00302" title="">Analysis 3.2</a>; <a href="./references#CD003046-fig-00401" title="">Analysis 4.1</a>; <a href="./references#CD003046-fig-00503" title="">Analysis 5.3</a>; <a href="./references#CD003046-fig-00504" title="">Analysis 5.4</a>). </p> <p>A separate post‐hoc analysis of the three trials conducted in Italy compared to the three trials conducted in Asia that compared RFA with PEI was performed. In Italian patients, there was no difference between treatment groups (HR 1.24; 95%; CI 0.84 to 1.83), while in Asian patients, the RFA seemed superior to PEI (HR 1.95; 95% CI 1.38 to 2.75). We found no statistically significant difference between the two subgroups (P value = 0.09) (<a href="./references#CD003046-fig-00603" title="">Analysis 6.3</a>). </p> </section> </section> <section id="CD003046-sec4-0020"> <h5 class="title">Comparison for safety outcomes</h5> <p>All studies reported on minor complications. In six trials (<a href="./references#CD003046-bbs2-0007" title="LencioniR , AllgaierHP , CioniD , OlschewskiM , DeibertP , CrocettiL , et al. Small hepatocellular carcinoma: randomized comparison of radio‐frequency thermal ablation and percutaneous ethanol injection. Radiology2003;228:235‐40. ">Lencioni 2003</a>; <a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0009" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI‐hd)</a>; <a href="./references#CD003046-bbs2-0010" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PAI)</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a>; <a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>; <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>), serious adverse events occurred. One trial reported a procedure‐related death within the PEI group (<a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>). The proportion of patients with a serious adverse event did not differ significantly between the compared intervention groups (PEI/PAI versus RFA; OR 0.70; 95% CI 0.33 to 1.48) (<a href="./references#CD003046-fig-00501" title="">Analysis 5.1</a>). </p> </section> <section id="CD003046-sec4-0021"> <h5 class="title">Comparison for economic outcomes</h5> <p>Duration of hospital stay was documented in three trials including five comparisons (<a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0009" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI‐hd)</a>; <a href="./references#CD003046-bbs2-0010" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PAI)</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a>). However, the settings of the trials differed due to regional habits. While <a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a> treated all patients as inpatients until treatment success was documented by computed tomography, PEI/PAI patients in the Lin trials were routinely treated as outpatients in the cases when there was no severe adverse effect during the first PEI/PAI session (<a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>). <a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a> reported a shorter hospitalisation time within the RFA group. These patients showed a shorter mean duration of hospital stay for the few complications that occurred. Due to the heterogeneous settings ‐ also demonstrated by high Chi<sup>2</sup> values and the small number of trials with available data, no valid conclusions can be deduced to date with regards to length of hospital stay (standardised mean difference ‐1.50; 95% CI ‐3.69 to 0.68). <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a> reported the cost of interventions and found PEI to be 100 times less expensive than RFA (EUR1359 versus EUR171,000, P value &lt; 0.0001). The study authors included the costs of the radiofrequency generator into this calculation. </p> </section> </section> <section id="CD003046-sec3-0028"> <h4 class="title">Radiofrequency ablation versus percutaneous microwave coagulation</h4> <section id="CD003046-sec4-0022"> <h5 class="title">Comparison for efficacy outcomes</h5> <p>Only one trial examined the effects of RFA versus percutaneous microwave coagulation. Shibata et al randomised 72 patients with 94 hepatic tumour nodules to RFA versus percutaneous microwave coagulation (<a href="./references#CD003046-bbs2-0012" title="ShibataT , IimuroY , YamamotoY , MaetaniY , AmetaniF , ItohK , et al. Small hepatocellular carcinoma: comparison of radio‐frequency ablation and percutaneous microwave coagulation therapy. Radiology2002;223:331‐7. ">Shibata 2002</a>). Data on overall survival, two‐year survival, and event‐free survival could not be extracted as the data presentation was based on tumour nodules and were not done patient‐wise. There was no significant difference between RFA and percutaneous microwave coagulation regarding local progression (HR 2.14; 95% CI 0.67 to 6.80) (<a href="./references#CD003046-fig-00401" title="">Analysis 4.1</a>). </p> </section> <section id="CD003046-sec4-0023"> <h5 class="title">Comparison for safety outcomes</h5> <p>No death or other serious adverse events were observed during the trial in the RFA or percutaneous microwave coagulation group. In the RFA group, one patient had a segmental hepatic infarction. In the percutaneous microwave coagulation group, one patient each developed liver abscess, cholangitis, subcutaneous abscess, and skin burn. The OR of major complications was 4.38 (95% CI 0.46 to 41.22). </p> </section> <section id="CD003046-sec4-0024"> <h5 class="title">Comparison for economic outcomes</h5> <p>There were no data for economic outcomes. Data on the duration of hospital stay were not presented. </p> </section> </section> <section id="CD003046-sec3-0029"> <h4 class="title">Radiofrequency ablation versus percutaneous laser ablation</h4> <p>One trial randomised 40 patients to RFA versus 41 patients to laser ablation (<a href="./references#CD003046-bbs2-0004" title="FerrariFS , MgliolaA , ScorzelliA , StellaA , VigniF , DrudiFM , et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long‐term results. La Radiologia Medica2007;112(3):377‐93. ">Ferrari 2007</a>). There were no significant differences between RFA and percutaneous laser ablation with regards to overall survival (HR 1.62; 95% CI 0.62 to 4.22) (<a href="./references#CD003046-fig-00101" title="">Analysis 1.1</a>), event‐free survival (HR 1.20; 95% CI 0.50 to 2.89) (<a href="./references#CD003046-fig-00301" title="">Analysis 3.1</a>), and local progression (HR 1.12; 95% CI 0.40 to 3.09) (<a href="./references#CD003046-fig-00401" title="">Analysis 4.1</a>).. </p> <section id="CD003046-sec4-0025"> <h5 class="title">Comparison for safety outcomes</h5> <p>There were no data reported on safety outcomes.</p> </section> <section id="CD003046-sec4-0026"> <h5 class="title">Comparison for economic outcomes</h5> <p>There were no data reported on economic outcomes.</p> </section> </section> <section id="CD003046-sec3-0030"> <h4 class="title">Quality of life</h4> <p>None of the identified trials reported on quality of life.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003046-sec1-0006" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003046-sec1-0006"></div> <p>Hepatocellular carcinoma represents a major health problem worldwide. Various therapeutic approaches such as percutaneous, transarterial, and surgical interventions are available. Prognosis and therapeutic options of patients with hepatocellular carcinoma depend on tumour extension and liver function, which is often reduced by underlying liver cirrhosis. Though sophisticated prognostic classifications such as the Barcelona Clinic Liver Cancer (BCLC), a more pragmatic approach based on number and size of tumour lesions is widely used to stratify patients (<a href="./references#CD003046-bbs2-0060" title="European Association for the Study of the Liver, European Organisation for Research and Treatment Of Cancer. EASL‐EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908‐43. ">EASL‐EORTC 2012</a>). The Milan criteria define "early hepatocellular carcinomas" as a single tumour of 5 cm or less or up to three tumours of 3 cm or less (<a href="./references#CD003046-bbs2-0083" title="MazzaferroV , RegaliaE , DociR , AndreolaS , PulvirentiA , BozzettiF , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine1996;334:693‐9. ">Mazzaferro 1996</a>). The Milan criteria are also used to evaluate patients for orthotopic liver transplantation. Advanced stages of disease include extensive liver involvement and extrahepatic disease. Intermediate stages are ill‐defined to date and belong to none of the former two groups. Furthermore, all treatments for hepatocellular carcinoma (excluding orthotopic liver transplantation) are reserved for patients with mild and moderate functional impairment of the liver. In our review, we aimed to determine the role of RFA as compared with any other intervention in patients with 'early hepatocellular carcinoma'. The primary outcome of our analyses was overall survival, which is the most relevant outcome for patients. </p> <section id="CD003046-sec2-0010"> <h3 class="title" id="CD003046-sec2-0010">Summary of main results</h3> <p>In contrast to two former versions of this systematic review (<a href="./references#CD003046-bbs2-0111" title="GalandiD , AntesG . Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma [Review]. The Cochrane Library (Update Software, Oxford) 2002, Issue 3. ">Galandi 2002</a>; <a href="./references#CD003046-bbs2-0112" title="GalandiD , AntesG . Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews2004, Issue 2. [DOI: 10.1002/14651858.CD003046] ">Galandi 2004</a>), new data on RFA for hepatocellular carcinoma has accumulated so that 11 randomised clinical trials have assessed RFA: three trials compared RFA versus resection (<a href="./references#CD003046-bbs2-0002" title="ChenMS , LiJQ , ZhengY , GoRP , LiangHH , ZhangYQ , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery2006;243(3):321‐8. ">Chen 2006</a>; <a href="./references#CD003046-bbs2-0006" title="HuangJ , YanL , ChengZ , WuH , DuL , WangJ , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Annals of Surgery2010;252(6):903‐12. ">Huang 2010</a>; <a href="./references#CD003046-bbs2-0003" title="FengK , YanJ , LiX , MaK , WangS , BieP , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology2012;57(4):794‐802. ">Feng 2012</a>); six trials RFA versus PEI (<a href="./references#CD003046-bbs2-0007" title="LencioniR , AllgaierHP , CioniD , OlschewskiM , DeibertP , CrocettiL , et al. Small hepatocellular carcinoma: randomized comparison of radio‐frequency thermal ablation and percutaneous ethanol injection. Radiology2003;228:235‐40. ">Lencioni 2003</a>; <a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a>; <a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>; <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>); one trial RFA versus PAI (<a href="./references#CD003046-bbs2-0010" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PAI)</a>; one trial RFA versus microwave ablation (<a href="./references#CD003046-bbs2-0012" title="ShibataT , IimuroY , YamamotoY , MaetaniY , AmetaniF , ItohK , et al. Small hepatocellular carcinoma: comparison of radio‐frequency ablation and percutaneous microwave coagulation therapy. Radiology2002;223:331‐7. ">Shibata 2002</a>); and one trial RFA versus laser ablation (<a href="./references#CD003046-bbs2-0004" title="FerrariFS , MgliolaA , ScorzelliA , StellaA , VigniF , DrudiFM , et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long‐term results. La Radiologia Medica2007;112(3):377‐93. ">Ferrari 2007</a>). This represents an expansion of nine new trials with 1643 new participants. </p> <section id="CD003046-sec3-0031"> <h4 class="title">Radiofrequency ablation versus hepatic resection</h4> <p>Our Cochrane systematic review included three randomised clinical trials comparing RFA versus surgical resection. Two of the identified trials had a low risk of bias (<a href="./references#CD003046-bbs2-0006" title="HuangJ , YanL , ChengZ , WuH , DuL , WangJ , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Annals of Surgery2010;252(6):903‐12. ">Huang 2010</a>; <a href="./references#CD003046-bbs2-0003" title="FengK , YanJ , LiX , MaK , WangS , BieP , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology2012;57(4):794‐802. ">Feng 2012</a>), while the third trial had a high risk of bias (<a href="./references#CD003046-bbs2-0002" title="ChenMS , LiJQ , ZhengY , GoRP , LiangHH , ZhangYQ , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery2006;243(3):321‐8. ">Chen 2006</a>). </p> <p>Analysing all three trials, there was no significant difference in the HR and the RR for overall survival (<a href="./references#CD003046-fig-00101" title="">Analysis 1.1</a>) and the HR for two‐year survival (<a href="./references#CD003046-fig-00201" title="">Analysis 2.1</a>) between the treatment groups, but we found the outcome to be in favour of the surgically treated patients regarding event‐free survival (<a href="./references#CD003046-fig-00301" title="">Analysis 3.1</a>) and local progression (<a href="./references#CD003046-fig-00401" title="">Analysis 4.1</a>). In the analysis of the two trials with a low risk of bias, hepatic resection resulted in an increased overall survival (<a href="./references#CD003046-fig-00202" title="">Analysis 2.2</a>) and increased two‐year survival (<a href="./references#CD003046-fig-00202" title="">Analysis 2.2</a>) when compared with RFA using traditional and naive statistical boundaries. We conclude that there is moderate‐quality evidence from randomised clinical trials that hepatic resection yields better results regarding benefits. However, the rate of complications is remarkably higher and the hospital stay is longer in the surgical resection group (<a href="./references#CD003046-fig-00501" title="">Analysis 5.1</a>). In order to become certain about the balance between benefits and harms, it would be necessary to conduct larger well‐designed randomised clinical trials (<a href="#CD003046-sec1-0009">Implications for research</a>). </p> </section> <section id="CD003046-sec3-0032"> <h4 class="title">Radiofrequency ablation versus local ablative interventions</h4> <p>In summary, our meta‐analysis adduces moderate‐quality evidence compiled from six randomised clinical trials that RFA seems superior to PEI/PAI regarding overall survival, two‐year survival, event‐free survival, and local recurrence, with a similar frequency of major complications (<a href="./references#CD003046-bbs2-0007" title="LencioniR , AllgaierHP , CioniD , OlschewskiM , DeibertP , CrocettiL , et al. Small hepatocellular carcinoma: randomized comparison of radio‐frequency thermal ablation and percutaneous ethanol injection. Radiology2003;228:235‐40. ">Lencioni 2003</a>; <a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a>; <a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>; <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>) (<a href="./full#CD003046-tbl-0002">summary of findings Table 2</a>). In the comparison of RFA versus PEI, the low technical and instrumental requirements for PEI should also be taken into consideration (<a href="./references#CD003046-bbs2-0097" title="SchoppmeyerK , WeisS , MössnerJ , FleigWE . Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD006745.pub2] ">Schoppmeyer 2009</a>). PEI may possibly also be a treatment option for very early hepatocellular carcinoma (single lesion 3 cm or less) (<a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>). There is evidence from single comparisons suggesting that RFA seems better than PAI and high‐dose PEI (<a href="./references#CD003046-bbs2-0009" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI‐hd)</a>; <a href="./references#CD003046-bbs2-0010" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PAI)</a>). RFA was only compared with laser ablation and microwave coagulation in one randomised clinical trial (<a href="./references#CD003046-bbs2-0012" title="ShibataT , IimuroY , YamamotoY , MaetaniY , AmetaniF , ItohK , et al. Small hepatocellular carcinoma: comparison of radio‐frequency ablation and percutaneous microwave coagulation therapy. Radiology2002;223:331‐7. ">Shibata 2002</a>; <a href="./references#CD003046-bbs2-0004" title="FerrariFS , MgliolaA , ScorzelliA , StellaA , VigniF , DrudiFM , et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long‐term results. La Radiologia Medica2007;112(3):377‐93. ">Ferrari 2007</a>). The trial comparing RFA versus laser ablation found no difference between treatment modalities regarding the outcomes event‐free survival and local progression (<a href="./references#CD003046-bbs2-0004" title="FerrariFS , MgliolaA , ScorzelliA , StellaA , VigniF , DrudiFM , et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long‐term results. La Radiologia Medica2007;112(3):377‐93. ">Ferrari 2007</a>). No survival data were available for microwave coagulation. In conclusion, among the available local ablative therapies, RFA seemed to be the most efficient and safe technique of all the assessed local ablative therapies. </p> <section id="CD003046-sec4-0027"> <h5 class="title">Italian versus East Asian trials</h5> <p>The trials comparing RFA versus PEI/PAI were performed either in Italy (<a href="./references#CD003046-bbs2-0007" title="LencioniR , AllgaierHP , CioniD , OlschewskiM , DeibertP , CrocettiL , et al. Small hepatocellular carcinoma: randomized comparison of radio‐frequency thermal ablation and percutaneous ethanol injection. Radiology2003;228:235‐40. ">Lencioni 2003</a>; <a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>; <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>), or in East‐Asia (<a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a>; <a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a>). Interestingly, there was no evidence for prolonged overall survival in European patients when treated with RFA compared with PEI (HR 1.24; 95% CI 0.84 to 1.83) (<a href="./full#CD003046-tbl-0003">summary of findings Table 3</a>), while East‐Asian studies suggested that overall survival was superior after RFA (HR 1.95; 95% CI 1.38 to 2.75). In one post‐hoc analysis, we compared both subgroups and found no significant difference between the groups (P value = 0.09). Therefore, undefined technical differences in tumour ablation, reporting bias, or chance might account for the difference between the European and Asian trials. However, this could be addressed in further trials. </p> </section> </section> <section id="CD003046-sec3-0033"> <h4 class="title">Ongoing trials</h4> <p>In addition to the included trial publications, we found three additional ongoing trials. One randomised clinical trial seeks information on RFA versus resection for hepatocellular carcinoma adjacent to large vessels (<a href="./references#CD003046-bbs2-0043" title="NCT00814242 . Hepatectomy versus radiofrequency ablation for hepatocellular carcinoma adjacent to major blood vessels. clinicaltrials.gov/ct2/show/NCT00814242 (accessed 16 December 2013). ">NCT00814242</a>). Randomised trials comparing (chemo‐)embolisation versus supportive care suggest that (chemo‐)embolisation may increase survival (<a href="./references#CD003046-bbs2-0078" title="LlovetJM , BruixJ , the Barcelona‐Clínic Liver Cancer Group. Systematic review of randomised trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology2003;37:429‐42. ">Llovet 2003</a>; <a href="./references#CD003046-bbs2-0079" title="LlovetJM , BurroughsA , BruixJ . Hepatocellular carcinoma. Lancet2003;362:1907‐17. ">Llovet 2003b</a>); however, one Cochrane systematic review found no convincing evidence that transarterial (chemo)embolisation was superior compared with no intervention for unresectable hepatocellular carcinoma (<a href="./references#CD003046-bbs2-0089" title="OliveriRS , WetterslevJ , GluudC . Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD004787.pub2] ">Oliveri 2011)</a>. We plan to include the information from these trials in the next update of our meta‐analysis. </p> </section> </section> <section id="CD003046-sec2-0011"> <h3 class="title" id="CD003046-sec2-0011">Overall completeness and applicability of evidence</h3> <p>Efficacy outcomes were properly addressed in most trials. However, this was not the case for the pre‐specified outcomes in this review, quality of life and health economics. None of the trials assessed effects of RFA on quality of life and only one trial reported on health economics. Giorgio et al. found RFA to be 100 times more expensive than PEI (<a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>). The study authors included the cost of the PEI needles and the cost of a radiofrequency generator. However, in contrast to the needles used for PEI, the generator can be used multiple times, and as such, this comparison has to be interpreted very cautiously. For the comparison between RFA and hepatic resection, only retrospective data with inherent high risk of bias are available. One Japanese working group compared medical costs in 213 patients who received either RFA or hepatic resection (<a href="./references#CD003046-bbs2-0070" title="IkedaK , KobayashiM , SaitohS , SomeyaT , HosakaT , SezakiH , et al. Cost‐effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3 cm or less in diameter. Hepatology Research2005;33(3):241‐9. ">Ikeda 2005</a>). Resection yielded lower recurrence rates as compared with RFA while increasing hospital stay. As a consequence, RFA had to be repeated in a higher number of patients. The study authors stated that repeated RFA was cheaper than resection (1,086,000 Japanese yen (JPY) versus 1,745,100 JPY; conversion rate 100 JPY = EUR0.71, at December 2013). </p> <p>The relevance of other alternative interventional therapies such as laser and microwave ablation remains undetermined. No randomised clinical trial compared RFA versus no treatment, with best supportive care, or with cryoablation. Given the large differences in survival between treatment and no treatment groups in cohort studies, randomised trials with an untreated arm are neither likely to be performed nor ethically justifiable. One unresolved problem of local percutaneous ablation techniques and hepatic resection is the appearance of disease at disseminated areas of the body, and the fact that new tumours often emerge in the remaining cirrhotic liver tissue. Orthotopic liver transplantation is the only treatment that also removes underlying cirrhosis. Randomised clinical trials comparing the effectiveness of RFA versus orthotopic liver transplantation or versus RFA as a bridging therapy to liver transplantation have not been performed. </p> <p>The current guidelines by the EASL and EORTC state that RFA is the interventional treatment of choice in patients that are not suitable for hepatic resection. If RFA is not feasible, PEI is recommended (<a href="./references#CD003046-bbs2-0060" title="European Association for the Study of the Liver, European Organisation for Research and Treatment Of Cancer. EASL‐EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908‐43. ">EASL‐EORTC 2012</a>). In our meta‐analysis, we found moderate evidence to support this recommendation, but too few patients were included in order to draw firm conclusion on the pre‐specified survival outcomes. To the best of our knowledge, this meta‐analysis is the first that includes the trials by <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a> and <a href="./references#CD003046-bbs2-0003" title="FengK , YanJ , LiX , MaK , WangS , BieP , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology2012;57(4):794‐802. ">Feng 2012</a> and thus it provides the best evidence available to date. </p> </section> <section id="CD003046-sec2-0012"> <h3 class="title" id="CD003046-sec2-0012">Quality of the evidence</h3> <p>The Cochrane Collaboration stresses the importance of good‐quality trials. It is recognised to date that methodological quality of trials influences estimates of intervention effects<i>(</i><a href="./references#CD003046-bbs2-0098" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD003046-bbs2-0085" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. ">Moher 1998</a>; <a href="./references#CD003046-bbs2-0072" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD003046-bbs2-0107" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336:601‐5. ">Wood 2008</a>; <a href="./references#CD003046-bbs2-0081" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>; <a href="./references#CD003046-bbs2-0095" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1‐82. ">Savovic 2012</a>; <a href="./references#CD003046-bbs2-0096" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savovic 2012a</a>). Considering possible sources of bias, we found five trials with low risk of bias. Six trials had methodological weaknesses that qualified them as trials with high risk of bias but were still eligible for inclusion (<a href="./references#CD003046-bbs2-0012" title="ShibataT , IimuroY , YamamotoY , MaetaniY , AmetaniF , ItohK , et al. Small hepatocellular carcinoma: comparison of radio‐frequency ablation and percutaneous microwave coagulation therapy. Radiology2002;223:331‐7. ">Shibata 2002</a>; <a href="./references#CD003046-bbs2-0002" title="ChenMS , LiJQ , ZhengY , GoRP , LiangHH , ZhangYQ , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery2006;243(3):321‐8. ">Chen 2006</a>; <a href="./references#CD003046-bbs2-0004" title="FerrariFS , MgliolaA , ScorzelliA , StellaA , VigniF , DrudiFM , et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long‐term results. La Radiologia Medica2007;112(3):377‐93. ">Ferrari 2007</a>; <a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a>; <a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a>; <a href="./references#CD003046-bbs2-0003" title="FengK , YanJ , LiX , MaK , WangS , BieP , et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology2012;57(4):794‐802. ">Feng 2012</a>). In summary, we found moderate‐quality evidence derived from six trials with 1088 participants that RFA is superior to PEI regarding efficacy outcomes, while at the same time, the risk of adverse events does not seem to differ between the two treatment modalities (<a href="./full#CD003046-tbl-0002">summary of findings Table 2</a>). As for the comparison between RFA and hepatic resection, there is moderate‐quality evidence from two low risk of bias trials that randomised 398 patients that hepatic resection is more effective than RFA regarding overall survival and two‐year survival. However, if a third trial with an additional 168 patients and a high risk of bias is included, the evidence becomes weak. With regards to the outcomes event‐free survival and local progression, hepatic resection was found to yield better results than RFA regardless of the inclusion of the third trial with high risk of bias. In order to strengthen the body of evidence, more trials with low risk of bias are needed. There is high‐quality evidence that complication rates were consistently higher in patients treated with hepatic resection (<a href="./full#CD003046-tbl-0001">summary of findings Table for the main comparison</a>). Due to their high risk of bias, no firm conclusions regarding the pre‐specified outcomes can be drawn for other interventional therapies. </p> <p>Trial sequential analysis revealed that less than half of the required number of patients was recruited into the eligible trials in order to judge an RRR of 20% (<a href="#CD003046-fig-0004">Figure 4</a>; <a href="#CD003046-fig-0005">Figure 5</a>). In addition, the calculation of the RR for the comparison RFA versus PEI did not reach statistical significance (<a href="./references#CD003046-fig-00102" title="">Analysis 1.2</a>). Therefore, we conclude that there is only moderate‐quality evidence to support RFA versus PEI or hepatic resection (<a href="./full#CD003046-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD003046-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD003046-sec2-0013"> <h3 class="title" id="CD003046-sec2-0013">Potential biases in the review process</h3> <p>We excluded two trials from the analysis as it was unclear whether they were randomised clinical trials. We tried to contact the study authors but did not receive any replies (<a href="./references#CD003046-bbs2-0021" title="GanYH , YieSH , RenZG , XiaJL , ZhangBH , WangYH , et al. Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma. Chinese Journal of Oncology2004;26(8):496‐8. ">Gan 2004</a>; <a href="./references#CD003046-bbs2-0017" title="ChenMS , ZhangYJ , LiJQ , LiangHH , ZhangYQ , ZhengY . Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency alone for small hepatocellular carcinoma. Chinese Journal of Oncology2005;27(10):623‐5. ">Chen 2005</a>). If these trials had been eligible for inclusion, we might have obtained information about the efficacy of RFA compared with chemotherapy and TACE. In addition, the two studies awaiting classification might have added important data to the meta‐analysis (<a href="./references#CD003046-bbs2-0041" title="DiCostanzoGG , TortoraR , D'AdamoG , Galeota LanzaA , CarannanteN , LampasiF , et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma: a randomized controlled trial. Journal of Hepatology2011;54(Suppl 1):S254‐S255. ">Di Costanzo 2011</a>; <a href="./references#CD003046-bbs2-0042" title="KuanshengM , FengK , YanJ , WangS , BieP . A randomized controlled study of radiofrequency ablation and surgical resection for early‐stage hepatocellular carcinomas less than 4 cm in diameter. Hepatology2011;54(S1):418A. ">Kuansheng 2011</a>). </p> </section> <section id="CD003046-sec2-0014"> <h3 class="title" id="CD003046-sec2-0014">Agreements and disagreements with other studies or reviews</h3> <section id="CD003046-sec3-0034"> <h4 class="title">Radiofrequency ablation compared with hepatic resection</h4> <p>Some non‐randomised studies (<a href="./references#CD003046-bbs2-0044" title="Abu‐HilalM , PrimroseJN , CasarilA , McPhailMJ , PearceNW , NicoliN . Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. Journal of Gastrointestinal Surgery2008;12(9):1521‐6. ">Abu‐Hilal 2008</a>; <a href="./references#CD003046-bbs2-0038" title="UenoS , SakodaM , KuboF , HiwatashiK , TatenoT , BabaY , et al. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. Journal of Hepato‐Biliary‐Pancreatic Surgery2009;16:359‐66. ">Ueno 2009</a>; <a href="./references#CD003046-bbs2-0019" title="ChoYK , KimJK , KimWT , ChungJW . Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology2010;51(4):1116‐8. ">Cho 2010</a>), one Markov model analysis (<a href="./references#CD003046-bbs2-0086" title="MolinariM , HeltonS . Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. American Journal of Surgery2009;198(3):396‐406. ">Molinari 2009</a>), and one prior meta‐analysis (<a href="./references#CD003046-bbs2-0109" title="ZhouY , ZhaoY , LiB , XuD , YinZ , XieF , et al. Meta‐analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterology2010;10:78. ">Zhou 2010</a>) reported superiority of hepatic resection as compared with RFA with regards to survival and recurrence. Although the post‐interventional morbidity was less in RFA‐treated patients, this did not significantly influence mortality. These results are in agreement with our review results. </p> </section> <section id="CD003046-sec3-0035"> <h4 class="title">Radiofrequency ablation compared with percutaneous ethanol injection or percutaneous acetic acid injection </h4> <p>In addition to the above mentioned meta‐analysis (<a href="./references#CD003046-bbs2-0109" title="ZhouY , ZhaoY , LiB , XuD , YinZ , XieF , et al. Meta‐analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterology2010;10:78. ">Zhou 2010</a>), three meta‐analyses on the effects of RFA on hepatocellular carcinoma have been published (<a href="./references#CD003046-bbs2-0055" title="ChoYK , KimJK , KimMY , RhimH , HanJK . Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology2009;49(2):453‐9. ">Cho 2009</a>; <a href="./references#CD003046-bbs2-0049" title="BouzaC , López‐CuadradoT , AlcázarR , Saz‐ParkinsonZ , AmateJM . Meta‐analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterology2009;9:31. ">Bouza 2009</a>; <a href="./references#CD003046-bbs2-0073" title="LauWY , LaiEC . The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Annals of Surgery2009;249(1):20‐5. ">Lau 2009</a>). Cho et al investigated the three‐year survival in randomised clinical trials comparing RFA versus PEI for small hepatocellular carcinoma (<a href="./references#CD003046-bbs2-0055" title="ChoYK , KimJK , KimMY , RhimH , HanJK . Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology2009;49(2):453‐9. ">Cho 2009</a>). The four identified trials were also included in our review. The Lencioni trial included in our analyses was not considered for missing three‐year survival rates. In accordance with our analyses, the study authors found evidence that RFA treatment was superior to PEI (OR 0.48; 95% CI 0.34 to 0.67, P value &lt; 0.001). Another meta‐analysis identified six studies that compared RFA versus PEI (<a href="./references#CD003046-bbs2-0049" title="BouzaC , López‐CuadradoT , AlcázarR , Saz‐ParkinsonZ , AmateJM . Meta‐analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterology2009;9:31. ">Bouza 2009</a>). An important difference to our analysis was that the previous authors included a quasi‐randomised trial (<a href="./references#CD003046-bbs2-0029" title="LivraghiT , GoldbergSN , LazzaroniS , MeloniF , SolbiatiL , GazelleGS . Small hepatocellular carcinoma: treatment with radio‐frequency ablation versus ethanol injection. Radiology1999;210(3):655‐61. ">Livraghi 1999</a>). The RR for one‐, two‐, three‐, and four‐year survival, the local recurrence rates as well as the complications were assessed. There was strong (overall survival, one‐year disease‐free survival, disease free‐survival, complete tumour response, major complications) or very strong (one‐, two‐, three‐year survival, total complications) evidence in favour of RFA versus PEI. Lau and Lai referred to four categories in their trial publication: RFA versus other ablative techniques, RFA for unresectable hepatocellular carcinoma, RFA as a bridging therapy for liver transplantation, and RFA for recurrent hepatocellular carcinoma after hepatectomy (<a href="./references#CD003046-bbs2-0073" title="LauWY , LaiEC . The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Annals of Surgery2009;249(1):20‐5. ">Lau 2009</a>). We acknowledge this holistic and thorough approach. However, there are some major differences to our work. First, existing data were included regardless of the quality of trials. For instance, the trial of <a href="./references#CD003046-bbs2-0030" title="LüMD , KuangM , LiangLJ , XieXY , PengBG , LiuGJ , et al. Surgical resection versus percutaneous thermal ablation for early‐stage hepatocellular carcinoma: a randomized clinical trial. National Medical Journal of China2006;86(12):801‐5. ">Lü 2006</a> was excluded from our analysis since effects of RFA were not extractable (see <a href="./references#CD003046-sec2-0019" title="">Characteristics of excluded studies</a> table). Second, quantitative meta‐analyses of the data were not performed. Thus, the conclusions presented there should be considered with caution. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003046-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram of the literature search as well as number and reasons of excluded studies." data-id="CD003046-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram of the literature search as well as number and reasons of excluded studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (survival outcomes)." data-id="CD003046-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (survival outcomes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study (survival outcomes)." data-id="CD003046-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (survival outcomes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis for the comparison radiofrequency ablation versus hepatic resection on mortality in patients with hepatocellular carcinoma. The diversity‐adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the percutaneous ethanol injection group (PEI); a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. The cumulative Z‐score never crossed the alpha‐spending monitoring boundary for harm and did not reach the beta‐spending monitoring boundaries (the area of futility), which was not even drawn by the program. Therefore, further randomised trials are needed." data-id="CD003046-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p><b>Trial sequential analysis for the comparison radiofrequency ablation versus hepatic resection on mortality in patients with hepatocellular carcinoma.</b> </p> <p>The diversity‐adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the percutaneous ethanol injection group (PEI); a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. The cumulative Z‐score never crossed the alpha‐spending monitoring boundary for harm and did not reach the beta‐spending monitoring boundaries (the area of futility), which was not even drawn by the program. Therefore, further randomised trials are needed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis for the comparison radiofrequency ablation versus percutaneous ethanol injection group (PEI) on mortality in patients with hepatocellular carcinoma.     The diversity‐adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the PEI group; a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. As it can be seen, the cumulative Z‐score has never crossed the alpha‐spending monitoring boundary for benefit and has not reached the beta‐spending monitoring boundary (the area of futility). Therefore, further randomised trials are needed." data-id="CD003046-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p><b>Trial sequential analysis for the comparison radiofrequency ablation versus percutaneous ethanol injection group (PEI) on mortality in patients with hepatocellular carcinoma.</b> <br/> <br/> The diversity‐adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the PEI group; a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. As it can be seen, the cumulative Z‐score has never crossed the alpha‐spending monitoring boundary for benefit and has not reached the beta‐spending monitoring boundary (the area of futility). Therefore, further randomised trials are needed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 1 Overall survival: control interventions versus RFA." data-id="CD003046-fig-00101" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 1 Overall survival: control interventions versus RFA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 2 Fixed‐effect model." data-id="CD003046-fig-00102" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 2 Fixed‐effect model.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 3 Trials with low risk of bias." data-id="CD003046-fig-00103" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 3 Trials with low risk of bias.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 4 Resection versus RFA, dichotomous outcome." data-id="CD003046-fig-00104" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 4 Resection versus RFA, dichotomous outcome.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall survival, Outcome 5 PEI or PAI versus RFA." data-id="CD003046-fig-00105" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Overall survival, Outcome 5 PEI or PAI versus RFA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Two‐year survival, Outcome 1 Control interventions versus RFA." data-id="CD003046-fig-00201" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Two‐year survival, Outcome 1 Control interventions versus RFA.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Two‐year survival, Outcome 2 Resection versus RFA, low risk of bias trials." data-id="CD003046-fig-00202" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Two‐year survival, Outcome 2 Resection versus RFA, low risk of bias trials.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Two‐year survival, Outcome 3 PEI or PAI versus RFA, low risk of bias trials." data-id="CD003046-fig-00203" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Two‐year survival, Outcome 3 PEI or PAI versus RFA, low risk of bias trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00301"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Event‐free survival, Outcome 1 Event‐free survival: control interventions versus RFA." data-id="CD003046-fig-00301" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Event‐free survival, Outcome 1 Event‐free survival: control interventions versus RFA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00301">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00302"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Event‐free survival, Outcome 2 PEI or PAI versus RFA, low risk of bias trials." data-id="CD003046-fig-00302" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Event‐free survival, Outcome 2 PEI or PAI versus RFA, low risk of bias trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00302">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00401"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Local progression/recurrences, Outcome 1 Local progression: control intervention versus RFA." data-id="CD003046-fig-00401" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Local progression/recurrences, Outcome 1 Local progression: control intervention versus RFA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00401">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00501"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Other secondary outcomes, Outcome 1 Rate of complications: RFA versus other interventions." data-id="CD003046-fig-00501" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Other secondary outcomes, Outcome 1 Rate of complications: RFA versus other interventions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00501">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00502"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Other secondary outcomes, Outcome 2 Rate of complications: PEI or PAI versus RFA." data-id="CD003046-fig-00502" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Other secondary outcomes, Outcome 2 Rate of complications: PEI or PAI versus RFA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00502">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00503"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Other secondary outcomes, Outcome 3 PEI/PAI versus RFA, low risk of bias trials." data-id="CD003046-fig-00503" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Other secondary outcomes, Outcome 3 PEI/PAI versus RFA, low risk of bias trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00503">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00504"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Other secondary outcomes, Outcome 4 Length of hospital stay; control interventions versus RFA (days)." data-id="CD003046-fig-00504" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Other secondary outcomes, Outcome 4 Length of hospital stay; control interventions versus RFA (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00504">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00505"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Other secondary outcomes, Outcome 5 Length of hospital stay; PEI or PAI versus RFA (days)." data-id="CD003046-fig-00505" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Other secondary outcomes, Outcome 5 Length of hospital stay; PEI or PAI versus RFA (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00505">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00601"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 PEI or PAI versus RFA, overall survival, other, Outcome 1 PEI versus RFA, dichotomous outcome." data-id="CD003046-fig-00601" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 PEI or PAI versus RFA, overall survival, other, Outcome 1 PEI versus RFA, dichotomous outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00601">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00602"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 PEI or PAI versus RFA, overall survival, other, Outcome 2 PEI/PAI versus RFA, low risk of bias trials." data-id="CD003046-fig-00602" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 PEI or PAI versus RFA, overall survival, other, Outcome 2 PEI/PAI versus RFA, low risk of bias trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00602">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003046-fig-00603"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/urn:x-wiley:14651858:media:CD003046:CD003046-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_t/tCD003046-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 PEI or PAI versus RFA, overall survival, other, Outcome 3 PEI versus RFA, Italian versus Asian trials." data-id="CD003046-fig-00603" src="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 PEI or PAI versus RFA, overall survival, other, Outcome 3 PEI versus RFA, Italian versus Asian trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-fig-00603">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/media/CDSR/CD003046/image_n/nCD003046-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003046-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hepatic resection compared with radiofrequency ablation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Hepatic resection compared with radiofrequency ablation for early hepatocellular carcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population: 578 patients with early HCC</b> </p> <p><b>Intervention: hepatic resection</b> </p> <p><b>Comparison: RFA</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Hazard ratio (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.44 to 1.15)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++O<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2‐year survival‐</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.51 (0.24 to 1.08)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++O<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Event‐free survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.54 to 0.91)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++O<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Local progression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.48 (0.28 to 0.82)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 trial reported on local progression.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate of complications</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.24 (2.12 to 31.95)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistical method is: odds ratio (M‐H, random, 95% CI)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay (days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.18 (1.97 to 2.39)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistical method is: standard. mean difference (IV, random, 95% CI)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; HCC: hepatocellular carcinoma; HR: hazard ratio; PAI: percutaneous acetic acid injection; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hepatic resection compared with radiofrequency ablation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003046-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Percutaneous ethanol injection compared with radiofrequency ablation for early hepatocellular carcinoma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Percutaneous ethanol injection compared with radiofrequency ablation for early hepatocellular carcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population: 1088 patients with early HCC</b> </p> <p><b>Intervention: PEI/PAI</b> </p> <p><b>Comparison: RFA</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Hazard ratio (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.64 (1.31 to 2.07)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1088</p> <p>(6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As there were 2 three‐armed trials, we report 6 trials with 8 comparisons.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2‐year survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.82 (1.34 to 2.47)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>715</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Event‐free survival</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.55 (1.31 to 1.85)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>949</p> <p>(5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Local progression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.44 (1.71 to 3.49)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>678</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate of complications</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.33 to 1.48)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1088</p> <p>(6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistical method is: odds ratio (M‐H, random, 95% CI).</p> <p>As there were 2 three‐armed trials, it is 5 studies with 7 comparisons.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of hospital stay</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐1.50 (‐3.69 to 0.68)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>576</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistical method is: standard. Mean difference (IV, random, 95% CI).</p> <p>As there were 2 three‐armed trials, it is 3 studies with 5 comparisons.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; HCC: hepatocellular carcinoma; HR: hazard ratio; PAI: percutaneous acetic acid injection; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Percutaneous ethanol injection compared with radiofrequency ablation for early hepatocellular carcinoma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003046-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clinical characteristics of patients treated with radiofrequency ablation or percutaneous ethanol injection</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""></td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b> Child‐Pugh </b> </p> </td> <td align="center" class="table-header" colspan="5" rowspan="1" valign=""> <p><b> Aetiology</b> </p> </td> <td align="center" class="table-header" colspan="4" rowspan="1" valign=""> <p><b>Tumour</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b> Overall survival</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Italian Trials </b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>A</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>B</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>HBV</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>HCV</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>HBC+HCV</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Alcohol</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Others</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Mean number of nodules</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>1 tumour</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Mean size</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Size &lt; 2 cm</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>HR (95% CI)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0001" title="BrunelloF , VeltriA , CarucciP , PaganoE , CicconeG , MorettoP , et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology2008;43:727‐35. ">Brunello 2008</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.65 to 2.01)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0005" title="GiorgioA , DiSarnoA , DeStefanoG , ScognamiglioU , FarellaN , MarinielloA , et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research2011;31(6):2291‐5. ">Giorgio 2011</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.71 to 2.14)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0007" title="LencioniR , AllgaierHP , CioniD , OlschewskiM , DeibertP , CrocettiL , et al. Small hepatocellular carcinoma: randomized comparison of radio‐frequency thermal ablation and percutaneous ethanol injection. Radiology2003;228:235‐40. ">Lencioni 2003</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.55 to 45.82)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Mean</i> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.84 to 1.83)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>East‐Asian Trials </b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0008" title="LinSM , LinCJ , LinCC , HsuCW , ChenYG . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology2004;127:1714‐23. ">Lin 2004 (RFA vs. PEI)</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.77</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.08 (1.02 to 4.20)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0011" title="LinSM , LinCJ , LinCC , HsuCW , ChenYC . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut2005;54(8):1151‐6. ">Lin 2005 (RFA vs. PEI)</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.01 (1.03 to 3.92)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003046-bbs2-0013" title="ShiinaS , TerataniT , ObiS , SatoS , TateishiR , FujishimaT , et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology2005;129(1):122‐30. ">Shiina 2005</a> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.73</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.86 (0.33 to 0.88)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Mean</i> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.95 (1.38 to 2.75)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Student's t‐test</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.s.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p>CI: confidence interval; HBV: hepatitis B virus; HCV: hepatitis C virus; HR: hazard ratio; n.s.: not significant (P value &gt; 0.05); PEI: percutaneous ethanol injection; RFA: radiofrequency ablation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clinical characteristics of patients treated with radiofrequency ablation or percutaneous ethanol injection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/full#CD003046-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003046-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall survival</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival: control interventions versus RFA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Resection versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.44, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 PEI or PAI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.31, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Laser ablation versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.62, 4.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fixed‐effect model <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.58, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Trials with low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.40, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Resection versus RFA, dichotomous outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.44, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 PEI or PAI versus RFA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.31, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 PEI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.27, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 PAI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [0.94, 3.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall survival</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003046-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Two‐year survival</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Control interventions versus RFA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Resection versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.24, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 PEI/PAI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.34, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Resection versus RFA, low risk of bias trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.17, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 PEI or PAI versus RFA, low risk of bias trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.41, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Two‐year survival</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003046-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Event‐free survival</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Event‐free survival: control interventions versus RFA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 PEI/PAI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.31, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Resection versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.54, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Laser ablation versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.50, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PEI or PAI versus RFA, low risk of bias trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.33, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Event‐free survival</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003046-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Local progression/recurrences</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Local progression: control intervention versus RFA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 PEI/PAI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [1.71, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Resection versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.28, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Microwave ablation versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [0.67, 6.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Laser ablation versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.40, 3.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Local progression/recurrences</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003046-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Other secondary outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Rate of complications: RFA versus other interventions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Resection versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.24 [2.12, 31.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 PEI/PAI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.33, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Microwave ablation versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.38 [0.46, 41.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Rate of complications: PEI or PAI versus RFA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.33, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 PEI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.37, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 PAI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 PEI/PAI versus RFA, low risk of bias trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Length of hospital stay; control interventions versus RFA (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Resection versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [1.97, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 PEI/PAI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐3.69, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Length of hospital stay; PEI or PAI versus RFA (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐3.69, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 PEI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.47 [‐4.23, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 PAI versus RFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.66 [‐2.16, ‐1.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Other secondary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003046-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">PEI or PAI versus RFA, overall survival, other</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 PEI versus RFA, dichotomous outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [0.97, 3.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PEI/PAI versus RFA, low risk of bias trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.46, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 PEI versus RFA, Italian versus Asian trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.24, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Italian trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.84, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Asian trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.38, 2.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">PEI or PAI versus RFA, overall survival, other</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003046.pub3/references#CD003046-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003046.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003046-note-1207">Español</a> </li> <li class="section-language"> <a class="" href="fr#CD003046-note-1206">Français</a> </li> <li class="section-language"> <a class="" href="ru#CD003046-note-1205">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003046-note-1208">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003046\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003046\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003046\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003046\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003046\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003046.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003046.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003046.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003046.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003046.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718065659"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003046.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718065663"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003046.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc73fa8d9f49c',t:'MTc0MDcxODA2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 